



University of Nebraska  
Medical Center  

---

Nebraska Medicine

2022 PAN PACIFIC  
**LYMPHOMA**  
CONFERENCE

July 18-22 • Grand Hyatt Kauai



# DOWNLOAD THE EVENT APP

Make the most of your conference experience by downloading the **FREE** mobile app!



## 1. Download and install the eventScribe app

Scan the QR code or search for **eventScribe** in the Apple App Store or in Google Play.

Enter **PPLC 2022** in the Search for an Event field.

## 2. Login to the conference app

To start using the conference app, select "**Create Account**" and type in **PPLC22** as the **event code**.

Enter **your name** and the **email address** that you used to register for this conference.

## 3. Check your email for your access code

Your access code is your password to login to the conference app.

## Laptop and Desktop Users



## 1. Visit the conference portal

Go to [www.eventscribe.net/2022/PPLC2022](http://www.eventscribe.net/2022/PPLC2022)

## 2. Login/Create an account

If this is the first time you are accessing the portal, click **Sign Up** to create an account.

Enter **your name** and the **email address** that you used to register for this conference.

Use **PPLC22** as the **event code**.

## 3. Check your email for your access code

Your access code is your password to login to the conference portal.

*We gratefully acknowledge the following for financial support of this conference:*

### GOLD SUPPORTERS

AstraZeneca Pharmaceuticals  
BeiGene USA, Inc.

### SILVER SUPPORTERS

AbbVie, Inc.  
Eli Lilly and Co.  
Kite Pharma, Inc.  
Seagen, Inc.  
Takeda Pharmaceuticals USA, Inc.

### BRONZE SUPPORTERS

ADC Therapeutics America, Inc.  
GlaxoSmithKline  
Incyte Corporation  
MorphoSys US, Inc.  
Pharmacyclics LLC, an AbbVie Company, and  
Janssen Biotech, Inc., administered by  
Janssen Scientific Affairs LLC

### COPPER SUPPORTERS

Acrotech Biopharma LLC  
Bristol Myers Squibb  
CTI Biopharma  
EUSA Pharma  
Genentech, Inc.  
Genmab US, Inc.  
Sanofi Genzyme

### EDUCATIONAL GRANTS

ADC Therapeutics America, Inc.  
AstraZeneca Pharmaceuticals  
Daiichi Sankyo, Inc.  
Eli Lilly and Co.  
Gilead Sciences, Inc. and Kite Pharma, Inc.  
Pharmacyclics LLC, an AbbVie Company, and  
Janssen Biotech, Inc., administered by  
Janssen Scientific Affairs LLC  
Seagen, Inc.



# Welcome to the 2022 Pan Pacific Lymphoma Conference!

Since its inception in 1994, PPLC has grown and become a premier international conference on the latest advances in lymphoma. This year, we have decided to host a hybrid conference with a live in-person activity at the Grand Hyatt Kauai, Hawaii and a virtual option for attendees who are not able to travel. We are very happy to welcome over 450 attendees!

For your easy reference and convenience, we encourage you to download the conference mobile app on your phone or tablet, or visit [www.eventscribe.net/2022/PPLC2022](http://www.eventscribe.net/2022/PPLC2022) if you are using a laptop or desktop computer.

Here's what you can expect for this engaging and productive week. Please note that all reference to conference days and times follow Hawaii Standard Time (HST).

- **Day 1 (Monday):** We will feature an Interprofessional Education Day, with various presentations for the entire lymphoma team members with sessions covering The Day-to-Day Treating of Lymphoma Patients and Provider and Patient Wellness.

- **Days 1-5 (Monday through Friday):** If you are joining us in person, please visit the exhibits in the Grand Ballroom and thank them for their support of this conference.

This year, the conference e-Poster gallery, detailing the latest research in lymphoma and transplantation, is available via the conference mobile app and the online conference portal.

- **Days 2-5 (Tuesday through Friday):** Expert faculty will present in scientific sessions covering Beginning and End, What Comes First?, Factors In Choosing Initial Therapy, Plasma Cell Dyscrasias, Why Did You Do That?, Tough Calls in NHL, Great Debates, Questionable Queries, Management of Orphan Diseases: When and How, and Top Prospects.

Alex Herrera, MD will present the James O. Armitage Lymphoma Clinical Investigator Award Lecture and Bruce D. Cheson, MD, FACP, FAAAS, FASCO will deliver the Oliver Press Memorial Lecture, in memory of our esteemed colleague, Oliver W. Press, MD, PhD.

- **Days 2-4 (Tuesday through Thursday) afternoons:** Join us for the Ask the Experts sessions where we will discuss Indolent Non-Hodgkin Lymphoma (iNHL), DLBCL, cHL, PTCL and Waldenström Macroglobulinemia/Multiple Myeloma. Also, on Tuesday, we will have our fast-paced Lymphoma Jeopardy with four teams competing for Wednesday's Pineapple Cup Lymphoma Jeopardy Finals.
- **Day 2 (Tuesday) evening:** If you are attending in-person, please join us for the Welcome Reception from 7-9 p.m. in the Shipwreck Lagoon area where you can meet and network with other conference attendees. Light hors d'oeuvres and beverages will be served. Paid/registered guests are welcome to attend.
- **Day 3 (Wednesday):** Please make time to join the industry-supported satellite symposium, Case Challenges in Chronic Lymphocytic Leukemia. If you haven't registered to attend this, you may do so online. Note that AMA and ANCC credits are available for this symposium held in conjunction with PPLC22.
- **Day 4 (Thursday) evening:** In-person attendees are encouraged to join the Conference Dinner from 7-9 p.m. in Ilima Garden. Dinner and beverages will be served. Paid/registered guests are welcome to attend.
- Friendly reminders if you are attending in-person: Please be sure that you and your paid guests wear your conference badge at all times.
- The attire for this conference is casual; layered clothing is recommended as temperature in meeting rooms can fluctuate. A light jacket or sweater for outdoor evening activities is suggested. Leave your ties in your room!
- If you are on Twitter or Instagram, we encourage you to tag your photos and posts **#PPLC22** and **#IamUNMC**.
- Once again, thank you for joining the 2022 Pan Pacific Lymphoma Conference. **Aloha!**

## Conference Directors



**James O. Armitage, MD**  
Joe Shapiro Professor of Medicine  
Division of Oncology and Hematology  
Department of Internal Medicine  
University of Nebraska Medical Center



**Matthew A. Lunning, DO, FACP**  
Associate Professor  
Division of Oncology and Hematology  
Department of Internal Medicine  
University of Nebraska Medical Center



**Julie M. Vose, MD, MBA**  
Neumann M. and Mildred E. Harris Professor  
Chief, Division of Oncology and Hematology  
Department of Internal Medicine  
University of Nebraska Medical Center

# CONFERENCE INFORMATION

---

## Conference Registration Information

The conference registration desk is located in the Grand Ballroom Promenade on the lobby level of the Grand Hyatt Kauai Resort & Spa. Attendees may pick up their conference materials and name badges at this location. The registration/information desk is open during the following times:

Sunday, July 17	2–4 p.m.
Monday, July 18	7 a.m. – 12:30 p.m.
Tuesday, July 19	7 a.m. – 12:30 p.m.
Wednesday, July 20	7 a.m. – 12:30 p.m.
Thursday, July 21	7 a.m. – 12:30 p.m.
Friday, July 22	7 a.m. – 12:30 p.m.

## Exhibit Hours

Monday, July 18	7 a.m. – 12:15 p.m.
Tuesday, July 19	7 a.m. – 1 p.m. / 3–5 p.m.
Wednesday, July 20	7 a.m. – 1 p.m. / 3–5 p.m.
Thursday, July 21	7 a.m. – 1 p.m. / 3–5 p.m.
Friday, July 22	7–10 a.m.

## Internet Access



Complimentary WiFi is available in the conference area.

Network: **UNMCPPLC22**

Password: **PPLC2022**

Complimentary in-room WiFi is available for guests of the Grand Hyatt Kauai Resort & Spa.

## Mobile Device Use

To make the most of your conference experience, we encourage you to use your mobile phone or tablet to access the conference app, or use your laptop or desktop to access the conference portal. See instructions on page 2.

Please remember to turn your mobile device to silent or vibrate mode when attending educational sessions.



## Photography and Audio Visual Recording Policy

Please be aware that during the 2022 Pan Pacific Lymphoma Conference, attendees, vendors, guests, and exhibitors may be photographed or videotaped by UNMC and/or third parties authorized by UNMC. Some of these photographs or videos may be displayed by UNMC in future publications or other materials. By virtue of your attendance, you agree to allow UNMC to use photographs of you in these promotional materials.

Photographs taken for the purpose of sharing on social media are allowed, but should avoid showing presentation slides. Please use **#PPLC22** and **#IamUNMC** when posting on social media.

## Children and Other Accompanying Guests

PPLC 2022 does not offer childcare services. Due to limited seating capacity and the highly technical nature of the program, children are not allowed to attend the educational sessions. For their safety, children must be accompanied by an adult at all times.


Registered accompanying guests may join conference registrants at the following food functions:

- Continental breakfasts (7–9 a.m.) and breaks as part of the main conference from Monday through Friday
- Welcome Reception on Tuesday evening
- Conference Dinner on Thursday evening

Name badges will be required for all attending these conference food functions.

## Venue Floor Plan / Session and Room Assignments

- 1 GRAND PROMENADE**  
Conference Registration
- 2 GRAND BALLROOM — 1, 2, 6, 7**  
Scientific Sessions  
Lymphoma Jeopardy (Wednesday)
- 3 GRAND BALLROOM — 3, 4, 5**  
Continental Breakfast  
Refreshment Breaks  
Exhibits
- 4 KAUAI BALLROOM**  
Lymphoma Jeopardy (Tuesday)  
Ask the Experts  
Satellite Symposium
- 5 SHIPWRECK LAGOON BEACH**  
Welcome Reception
- 6 ILIMA GARDEN**  
Conference Dinner



# CONFERENCE AGENDA

 All times are displayed in Hawaii Standard Time (HST)

## Monday, July 18

### INTERPROFESSIONAL EDUCATION DAY

7:00 a.m. Conference Registration **1** Continental Breakfast **3**

7:45 a.m. Welcome **2**  
Matthew A. Lunning, DO, FACP

### SCIENTIFIC SESSIONS **2**

#### The Day-to-Day Treating of Lymphoma Patients

MODERATOR: Kim Schmit-Pokorny, RN, MSN, OCN, BMTCN

8:00 a.m. Infectious Disease Prophylaxis  
Andrea J. Zimmer, MD, FACP

8:30 a.m. Dose Reductions  
Jared E. Matya, PharmD, BCOP

9:00 a.m. Transfusion Medicine  
Scott Koepsell, MD, PhD

9:30 a.m. Fertility Preservation  
Elizabeth S. Constance, MD, FACOG

10:00 a.m. Break **3**

#### Provider and Patient Wellness

MODERATOR: Bradly Vlcek, BSN, RN, OCN

10:20 a.m. Survivorship  
Rachael L. Schmidt, DNP, FNP-C, AOCNP®

11:05 a.m. Burnout  
David S. Kroll, MD

11:35 a.m. Mental Health  
Christopher J. Kratochvil, MD

12:15 p.m. Adjourn

## Tuesday, July 19

7:00 a.m. Conference Registration **1** Continental Breakfast **3**

7:30 a.m. Welcome **2**  
James O. Armitage, MD and Julie M. Vose, MD, MBA

### SCIENTIFIC SESSIONS **2**

#### Beginning and End

MODERATOR: Julie M. Vose, MD, MBA

7:40 a.m. Epigenetic Insights in Lymphomagenesis  
Michael R. Green, PhD

8:05 a.m. Molecular Insights in Lymphomagenesis  
David W. Scott, MBChB, PhD

8:30 a.m. Difficult Diagnoses in Lymphoma  
Lisa M. Rimsza, MD

8:55 a.m. Incorporating Imaging Modalities into Serologic Response Measures  
Craig M. Johnson, MD

9:20 a.m. Incorporating Serologic Response Measures into Imaging Modalities  
David M. Kurtz, MD, PhD

9:50 a.m. Break **3**

#### What Comes First? Factors In Choosing Initial Therapy

MODERATOR: Theresa Franco, MSN, RN

10:05 a.m. Early-Stage Classical Hodgkin Lymphoma (cHL)  
Alison J. Moskowitz, MD

10:30 a.m. Advanced Stage cHL  
Ann S. LaCasce, MD, MMSc

10:55 a.m. Primary Central Nervous System (CNS) Lymphoma  
Avyakta Kallam, MBBS

11:20 a.m. Peripheral T-cell Lymphoma (PTCL)  
Neha Mehta-Shah, MD, MSCI

**Plasma Cell Dyscrasias**

MODERATOR: Christopher D'Angelo, MD

**11:45 a.m.** Monoclonal Gammopathies of Significance  
Nina Shah, MD**12:10 p.m.** Evaluation and Management of Light Chain (AL)  
Amyloidosis  
Angela Dispenzieri, MD**12:35 p.m.** Adjourn**LYMPHOMA JEOPARDY****3:00 p.m.** Pineapple Cup Semifinals #1  
*Team 1:* Brad S. Kahl, MD and Neha Mehta-Shah, MD, MSCI  
*Team 2:* Allison J. Moskowitz, MD and Andrew D. Zelenetz, MD, PhD  
*Team 3:* Matthew S. Davids, MD, MMSc and Ann S. LaCasce, MD, MMScPineapple Cup Semifinals #2  
*Team 1:* Alex Herrera, MD and Jasmine M. Zain, MD  
*Team 2:* Loretta J. Nastoupil, MD and Jason R. Westin, MD, MS, FACP  
*Team 3:* Jeremy S. Abramson, MD, MMSc and Irene M. Ghobrial, MD**ASK THE EXPERTS****4:00 p.m.** Indolent Non-Hodgkin Lymphoma (iNHL)  
MODERATOR: James O. Armitage, MD  
Christopher D'Angelo, MD; Loretta J. Nastoupil, MD; and Tycel  
Jovelle Phillips, MD**5:00 p.m.** Adjourn**WELCOME RECEPTION****7:00-9:00 p.m.**  
Conference participants and registered accompanying guests are invited to join the reception. Name badges required.**Wednesday, July 20****7:00 a.m.** Continental Breakfast**SCIENTIFIC SESSIONS****Why Did You Do That?**

MODERATOR: Jeffrey P. Gold, MD

**7:30 a.m.** Primary Refractory Diffuse Large B-cell Lymphoma (DLBCL)  
Laurie H. Sehn, MD, MPH and Jason R. Westin, MD, MS, FACP**8:00 a.m.** Bridging To CAR-T  
Caron A. Jacobson, MD, MMSc and Frederick Locke, MD**8:30 a.m.** CAR-T and Auto-Ineligible DLBCL  
Jeremy S. Abramson, MD, MMSc and Joshua Brody, MD**9:00 a.m.** Mantle Cell Lymphoma (MCL) in First Complete Response  
Brad S. Kahl, MD and Julie M. Vose, MD, MBA**9:30 a.m.** Transplant-Eligible Relapsed cHL  
Ranjana H. Advani, MD and Craig H. Moskowitz, MD**10:00 a.m.** Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) During COVID-19  
John P. Leonard, MD and Loretta J. Nastoupil, MD**10:30 a.m.** Break

MODERATORS: Matthew A. Lunning, DO, FACP and Julie M. Vose, MD, MBA

**10:50 a.m.** James O. Armitage Lymphoma Clinical Investigator Award  
Alex Herrera, MD**11:20 a.m.** Oliver Press Memorial Lecture  
Bruce D. Cheson, MD, FACP, FAAAS, FASCO

# CONFERENCE AGENDA

 All times are displayed in Hawaii Standard Time (HST)

## LYMPHOMA JEOPARDY 2

**11:50 a.m.** Finals

**12:30 p.m.** Adjourn

## SATELLITE SYMPOSIUM 4

**12:45 p.m.** Case Challenges in Chronic Lymphocytic Leukemia  
*Administered by Medscape Oncology*  
Supported by educational grants from AstraZeneca Pharmaceuticals and Pharmacyclics LLC, an AbbVie Company

**2:45 p.m.** Adjourn

## ASK THE EXPERTS 4

**3:00 p.m.** DLBCL  
MODERATOR: James O. Armitage, MD  
Jeremy S. Abramson, MD, MMSc; Laurie H. Sehn, MD, MPH; and Andrew D. Zelenetz, MD, PhD

**4:00 p.m.** cHL  
MODERATOR: Avyakta Kallam, MBBS  
Ranjana H. Advani, MD; Ann S. LaCasce, MD, MMSc; and Alison J. Moskowitz, MD

**5:00 p.m.** Adjourn

## Thursday, July 21

**7:00 a.m.** Continental Breakfast 3

## SCIENTIFIC SESSIONS 2

### Tough Calls in NHL

MODERATOR: Matthew A. Lunning, DO, FACP

**7:30 a.m.** A Case of FL  
R. Gregory Bociek, MD, MSc, FRCP(C); John P. Leonard, MD; and Loretta J. Nastoupil, MD

**8:00 a.m.** A Case of MCL  
Nilanjan Ghosh, MD, PhD; Brad S. Kahl, MD; and Andrew D. Zelenetz, MD, PhD

### Great Debates

MODERATOR: James O. Armitage, MD

**8:30 a.m.** Autologous Transplantation After BV-CHP in CD30 Expressing PTCL  
*For:* Jasmine M. Zain, MD  
*Against:* Steven M. Horwitz, MD

**9:00 a.m.** Autologous Transplantation for DLBCL  
*For:* Craig S. Sauter, MD  
*Against:* Jeremy S. Abramson, MD, MMSc

**9:30 a.m.** CAR-T for iNHL  
*For:* Caron A. Jacobson, MD, MMSc  
*Against:* Frederick Locke, MD

**10:00 a.m.** Break 3

### Questionable Queries

MODERATOR: Christopher J. Kratochvil, MD

**10:20 a.m.** Is There a Right Management of Richter's Transformation?  
Matthew S. Davids, MD, MMSc

**10:45 a.m.** How Many Drugs Are Needed in Front Line Chronic Lymphocytic Leukemia (CLL)?  
Anthony R. Mato, MD, MSCE



**11:10 a.m.** Can Bispecific T-cell Engagers (BiTES), Chimeric Antigen Receptors (CARs), and Antibody-Drug Conjugates (ADCs) Play in the Sandbox Together?  
Andrew D. Zelenetz, MD, PhD

**11:35 a.m.** Should We Be Treating p53 Mutated MCL Differently?  
Tycel Jovelle Phillips, MD

**12:00 p.m.** Is Progression of Disease Within 24 Months (POD24) A Real Population?  
Richard I. Fisher, MD

**12:30 p.m.** Adjourn

## ASK THE EXPERTS 4

**3:00 p.m.** PTCL  
MODERATOR: Matthew A. Lunning, DO, FACP  
Steven M. Horwitz, MD; Neha Mehta-Shah, MD, MSCI; and Jasmine M. Zain, MD

**4:00 p.m.** Waldenström Macroglobulinemia/Multiple Myeloma  
Moderator: Christopher D'Angelo, MD  
Angela Dispenzieri, MD; Irene M. Ghobrial, MD; and Nina Shah, MD

**5:00 p.m.** Adjourn

## CONFERENCE DINNER 6

**7:00-9:00 p.m.**  
Conference participants and registered accompanying guests are invited to join. Name badges required.

# Friday, July 22

**7:00 a.m.** Continental Breakfast 3

## SCIENTIFIC SESSIONS 2

**Management of Orphan Diseases: When and How**  
MODERATOR: Matthew A. Lunning, DO, FACP

**7:30 a.m.** When and How To Treat Castleman's Disease  
Sudipto Mukherjee, MD, MPH

**7:55 a.m.** When and How To Treat Early-Stage Mycosis Fungoides  
Ashley Wysong, MD, MS

**8:20 a.m.** When and How To Treat Waldenström Macroglobulinemia  
Irene M. Ghobrial, MD

**8:45 a.m.** When and How To Treat Localized Extranodal MZL  
R. Gregory Bociek, MD, MSc, FRCP(C)

**9:10 a.m.** When and How To Treat Lymphomatoid Papulosis (LyP)  
Steven M. Horwitz, MD

**9:35 a.m.** Break 3

## Top Prospects

MODERATOR: Matthew A. Lunning, DO, FACP

**9:55 a.m.** Future Therapies: DLBCL  
Christopher D'Angelo, MD

**10:20 a.m.** Future Therapies: FL  
Jonathan W. Friedberg, MD, MMSc

**10:45 a.m.** Future Therapies: HL  
Stephen M. Ansell, MD, PhD

**11:10 a.m.** Future Therapies: PTCL  
Neha Mehta-Shah, MD, MSCI

**11:35 a.m.** Take Home Messages  
Matthew A. Lunning, DO, FACP

**11:50 a.m.** Adjourn

# CONFERENCE FACULTY

## **Jeremy S. Abramson, MD, MMSc**

Director, Jon and Jo Ann Hagler Center for Lymphoma, Massachusetts General Hospital; Associate Professor of Medicine, Harvard Medical School, Boston, MA

## **Ranjana H. Advani, MD**

Saul A. Rosenberg Professor of Lymphoma, Department of Medicine/Oncology, Stanford Cancer Institute, Stanford University Medical Center, Stanford, CA

## **Stephen M. Ansell, MD, PhD**

Chair, Mayo Clinic Lymphoma Group; Professor of Medicine, Mayo Clinic, Rochester, MN

## **James O. Armitage, MD** ★

Joe Shapiro Professor of Medicine, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

## **R. Gregory Bociek, MD, MSc, FRCP(C)**

Associate Professor, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

## **Joshua Brody, MD**

Director of the Lymphoma Immunotherapy Program, The Tisch Cancer Institute; Associate Professor, Medicine, Hematology and Medical Oncology and Oncological Sciences, The Mount Sinai Hospital, New York, NY

## **Bruce D. Cheson, MD, FACP, FAAAS, FASCO**

Scientific Advisor to the Lymphoma Research Foundation, Bethesda, MD

## **Elizabeth S. Constance, MD, FACOG**

Director of Fertility Preservation Services, Heartland Center for Reproductive Medicine; Assistant Professor, Reproductive Endocrinology/Infertility, Department of Obstetrics and Gynecology, University of Nebraska Medical Center, Omaha, NE

## **Christopher D'Angelo, MD**

Assistant Professor, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

## **Matthew S. Davids, MD, MMSc**

Associate Professor of Medicine, Harvard Medical School; Director of Clinical Research, Division of Lymphoma, Dana-Farber Cancer Institute, Boston, MA

## **Angela Dispenzieri, MD**

Professor, Division of Hematology, Department of Internal Medicine; Professor, Department of Laboratory Medicine and Pathology; Chair of Hematology Research, Mayo Clinic, Rochester, MN

## **Richard I. Fisher, MD**

Former President and CEO, Fox Chase Cancer Center, Philadelphia, PA

## **Theresa Franco, MSN, RN**

Vice President, Cancer Center Clinical Operations, Fred & Pamela Buffett Cancer Center, Nebraska Medicine, Omaha, NE

## **Jonathan W. Friedberg, MD, MMSc**

Director, James P. Wilmot Cancer Institute; Samuel Durand Professor of Medicine, University of Rochester Medical Center, Rochester, NY

## **Irene M. Ghobrial, MD**

Director, Clinical Investigator Research Program; Lavine Family Chair for Preventative Cancer Therapies; Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA

## **Nilanjan Ghosh, MD, PhD**

Associate Professor, Medicine, University of North Carolina School of Medicine; Lymphoma Program Director, Levine Cancer Institute Morehead, Charlotte, NC

## **Jeffrey P. Gold, MD**

Executive Vice President and Provost, University of Nebraska System; Chancellor, University of Nebraska Medical Center, Omaha, NE

## **Michael R. Green, PhD**

Associate Professor; Director, Translational and Laboratory Research, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

## **Alex Herrera, MD**

Associate Professor, Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA

## **Steven M. Horwitz, MD**

Member and Attending Physician, Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

## **Caron A. Jacobson, MD, MMSc**

Medical Director, Immune Effector Cell Therapy Program; Senior Physician; Assistant Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA

## **Craig M. Johnson, MD**

Assistant Professor, Nuclear and Neuroradiology; Section Chief, Nuclear Medicine, Department of Radiology, University of Nebraska Medical Center, Omaha, NE

## **Brad S. Kahl, MD**

Professor of Medicine; Director, Lymphoma Program, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO

## **Avyakta Kallam, MBBS**

Assistant Professor, Division of Hematology and Oncology, Department of Internal Medicine, Omaha, NE

## **Scott Koepsell, MD, PhD**

Associate Professor, Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE

## **Christopher J. Kratochvil, MD**

Global Center for Health Security Distinguished Chair; Associate Vice Chancellor for Clinical Research, University of Nebraska Medical Center; Vice President for Research, Nebraska Medicine, Omaha, NE

## **David S. Kroll, MD**

Associate Vice Chair for Program Development and Innovation, Department of Psychiatry, Brigham Health, Boston, MA

## **David M. Kurtz, MD, PhD**

Assistant Professor, Division of Oncology, Department of Medicine, Stanford University Medical Center, Stanford Cancer Institute, Palo Alto, CA

★ Conference Director

**Ann S. LaCasce, MD, MMSc**

Director, Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology; Fellowship Program in Hematology/Oncology Chair; Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA

**John P. Leonard, MD**

Richard T. Silver Distinguished Professor of Hematology and Medical Oncology; Associate Dean for Clinical Research, Executive Vice Chairman, Weill Department of Medicine, Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY

**Frederick L. Locke, MD**

Vice Chair, Department of Blood and Marrow Transplant and Cellular Immunotherapy, Program Co-Leader, Immuno-Oncology, Moffitt Cancer Center, Tampa, FL

**Matthew A. Lunning, DO, FACP** ★

Associate Professor, Division of Oncology and Hematology, Department of Internal Medicine; Assistant Vice Chancellor for Clinical Research, University of Nebraska Medical Center, Omaha, NE

**Anthony R. Mato, MD, MSCE**

Director, CLL Program, Memorial Sloan Kettering Cancer Center, New York, NY

**Jared E. Matya, PharmD, BCOP**

Focused Population Pharmacist, Blood and Marrow Transplant, Nebraska Medicine, Omaha, NE

**Neha Mehta-Shah, MD, MSCI**

Assistant Professor, Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO

**Alison J. Moskowitz, MD**

Associate Attending, Clinical Director, Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

**Craig H. Moskowitz, MD**

Physician in Chief, Cancer Service Line, Sylvester Comprehensive Cancer Center; Professor of Medicine, Miller School of Medicine, University of Miami Health System, Miami, FL

**Sudipto Mukherjee, MD, PhD, MPH**

Director of Rare Cancers and Blood Diseases; Assistant Professor, Lerner College of Medicine at Case Western Reserve University; Cleveland Clinic Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland, OH

**Loretta J. Nastoupil, MD**

Lead, Early Phase Drug Development, Division of Cancer Medicine, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

**Tysel Jovelle Phillips, MD**

Clinical Associate Professor, University of Michigan Health, Michigan Medicine, Ann Arbor, MI

**Lisa M. Rimsza, MD**

Professor, Department of Laboratory Medicine and Pathology, Mayo Clinic, Phoenix, AZ

**Craig S. Sauter, MD**

Director, Blood and Marrow Transplant Program, Cleveland Clinic, Cleveland, OH

**Rachael L. Schmidt, DNP, FNP-C, AOCNP®**

Program Director, Cancer Survivorship, Cancer Risk and Prevention, Nebraska Medicine, Omaha, NE

**Kim Schmit-Pokorny, RN, MSN, OCN, BMTCN**

Director, Blood and Marrow Transplantation Program, CAR T and Cellular Therapy Program, Apheresis Department, Nebraska Medicine, Omaha, NE

**David W. Scott, MBChB, PhD**

Deputy Head, Department of Lymphoid Cancer Research; Clinical Director, Centre for Lymphoid Cancer; Associate Professor, Faculty of Medicine, University of British Columbia, BC Cancer Research Institute, Vancouver, BC, Canada

**Laurie H. Sehn, MD, MPH**

Chair, Lymphoma Tumour Group, British Columbia Cancer Centre for Lymphoid Cancer; Clinical Professor of Medicine, Division of Medical Oncology, University of British Columbia, Vancouver, BC, Canada

**Nina Shah, MD**

Professor, Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA

**Bradly Vitek, BSN, RN, OCN**

Nurse Case Manager, Division of Hematology and Oncology, Nebraska Medicine, Omaha, NE

**Julie M. Vose, MD, MBA** ★

Neumann M. and Mildred E. Harris Professor and Chief, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

**Jason R. Westin, MD, MS, FACP**

Associate Professor; Section Chief, Aggressive Lymphoma; Director, Lymphoma Clinical Research Program, Division of Cancer Medicine, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

**Ashley Wysong, MD, MS**

Founding Chair; William W. Bruce MD Distinguished Chair, Department of Dermatology, University of Nebraska Medical Center, Omaha, NE

**Jasmine M. Zain, MD**

Professor, Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation; Director, T-cell Lymphoma Program; Toni Stephenson Lymphoma Center, City of Hope, Duarte, CA

**Andrew D. Zelenetz, MD, PhD**

Medical Director, Quality Informatics; Attending Physician, Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center; Professor of Medicine, Weill Cornell Medicine, New York, NY

**Andrea J. Zimmer, MD, FACP**

Assistant Professor, Division of Infectious Diseases; Director, Oncology Infectious Diseases Program; Associate Program Director, Infectious Diseases Fellowship, University of Nebraska Medical Center, Omaha, NE

# EDUCATION INFORMATION

---

## Target Audience

The 2022 Pan Pacific Lymphoma Conference is one of the largest gatherings of clinicians and researchers specializing in the areas of lymphoma and transplantation. The 2022 conference will benefit members of the multidisciplinary lymphoma clinical team including oncologists, hematologists, pathologists, clinical scientists, nurse practitioners, physician assistants, nurses, and pharmacists.

## Conference Objectives

At the conclusion of the conference, the participant should be better able to:

1. Discuss common strategies and treatments in the management of lymphoma involving infectious disease prophylaxis, situations for consideration of therapy dose reductions, transfusion pharmacotherapeutics, orphan drugs, and fertility preservation
2. Identify factors related to provider burnout and the impact of its circumstances on patients' and providers' well-being
3. Describe the molecular insights of lymphomagenesis and the pathological pathway to diagnosis of difficult cases
4. Discuss how minimal residual disease and imaging technologies can be incorporated to assist in improving treatment response evaluations
5. Assess novel and future therapies for the initial treatment of classical Hodgkin lymphoma (cHL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), primary central nervous system (CNS) lymphoma, and peripheral T-cell lymphomas (PTCL)
6. Evaluate the diverse landscape of monoclonal gammopathies of significance and the intersection of plasma cell dyscrasias
7. Analyze clinical trial results concerning prognosis and transplant-eligibility criteria for patients with relapsed cHL, FL, marginal zone lymphoma (MZL), and primary refractory DLBCL
8. Differentiate approaches to treatment for relapsed DLBCL between the need for autologous transplantation versus CAR-T therapy
9. Explain the roles of the interprofessional health care team in the diagnosis, treatment, management, and support of lymphoma and hematologic malignancies

## Continuing Education Credits



JOINTLY ACCREDITED PROVIDER™  
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

### PHYSICIANS

The University of Nebraska Medical Center designates this live activity for a maximum of 28 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### NURSES

The University of Nebraska Medical Center designates this activity for up to 28 ANCC contact hours. Nurses should only claim credit for the actual time spent in the activity.

### PHARMACISTS

The University of Nebraska Medical Center designates this activity for 28 ACPE contact hours. Pharmacists should claim only the credit commensurate with the extent of their participation in the activity. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion. UAN # JA0000319-0000-21-004-L01-P

## Maintenance of Certification (MOC)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

28 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.

28 MOC points in the American Board of Pathology's (ABPATH) Maintenance of Certification (MOC) program.

It is the CME Provider's responsibility to submit participant completion information to ACCME for the purpose of granting MOC credit.


# DISCLOSURE INFORMATION

## How to Claim Continuing Education Credit



**To obtain continuing education credit, you must complete the conference evaluation.**

- On your mobile phone or tablet, sign in to the conference app and click the Claim Credit/MOC/Conference Evaluation tile.
- Using a laptop or desktop, sign in to the conference portal and go to Claim Credit/MOC/Conference Evaluation.

 Please make sure to update your account profile information.

### FOR PHYSICIANS CLAIMING AMA AND MOC CREDIT:

- Complete the pretest for MOC credit
- Select the Scientific Sessions you attended and complete the evaluation for each session
- Complete the general conference evaluation
- Complete the post test for MOC credit
- Retrieve your certificate

### FOR PHYSICIANS AND OTHER HEALTH CARE PROVIDERS CLAIMING AMA OR ANCC CREDIT:

- Select the Scientific Sessions you attended and complete the evaluation for each session
- Complete the general conference evaluation
- Retrieve your certificate

### FOR PHARMACISTS CLAIMING ACPE CREDIT:

- Make sure your date of birth (mm/dd) and NABP ID# are entered in your profile. (Your NABP ID# is different from your license number).
- Select the Scientific Sessions you attended and complete the evaluation for each session
- Complete the general conference evaluation



You have up to **September 18, 2022** to complete the evaluation and claim credit for participation.

## Disclosure Declaration

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. Faculty (authors, presenters, speakers) are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or other options available when utilizing trade names to ensure impartiality.

All faculty, planners, and others in a position to control continuing education content participating in a UNMC accredited activity are required to disclose all financial relationships with ineligible companies. As defined by the Standards for Integrity and Independence in Accredited Continuing Education, ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles:

### THE FOLLOWING FACULTY MEMBERS HAVE DISCLOSED RELEVANT FINANCIAL RELATIONSHIPS:

**Jeremy S. Abramson, MD, MMSc**

CONSULTANT: AbbVie; Bristol Myers Squibb; Genentech/Roche

CONSULTING FEES: AbbVie; Bristol Myers Squibb; Genentech/Roche

**Ranjana H. Advani, MD**

ADVISORY BOARD: Epizyme; MorphoSys US, Inc.

RESEARCH FUNDING: Janssen; Seattle Genetics

# DISCLOSURE INFORMATION

---

## **Stephen M. Ansell, MD, PhD**

GRANT/RESEARCH SUPPORT: ADC Therapeutics; Bristol Myers Squibb; Regeneron; Seattle Genetics; Trillium Therapeutics, Inc.

RESEARCH FUNDING: ADC Therapeutics; AstraZeneca; Bristol Myers Squibb; Regeneron; Seattle Genetics; Takeda; Trillium Therapeutics, Inc.

## **James O. Armitage, MD**

MEMBER, BOARD OF DIRECTORS: Cardiff Oncology

## **R. Gregory Bociek, MD, MSc, FRCP(C)**

CONSULTANT: Innate Pharma

## **Bruce D. Cheson, MD, FACP, FAAAS, FASCO**

ADVISORY BOARD: AbbVie; AstraZeneca; BeiGene; Epizyme; MorphoSys US, Inc.; Protagonist; Symbio

BOARD OF DIRECTORS: Symbio

CONSULTANT: TG Therapeutics

CONSULTING: AbbVie; ADC Therapeutics; BeiGene; Epizyme; MorphoSys US, Inc.; Protagonist; TG Therapeutics

GRANT/RESEARCH SUPPORT: Epizyme, TG Therapeutics

SPEAKERS BUREAU: BeiGene; MorphoSys US, Inc.; TG Therapeutics

## **Elizabeth S. Constance, MD, FACOG**

CO-OWNER: Heartland Center for Reproductive Medicine

## **Christopher D'Angelo, MD**

CONSULTING: TG Therapeutics

## **Matthew S. Davids, MD, MMSc**

ADVISORY BOARD: AbbVie, Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, BeiGene, Eli Lilly, Janssen, TG Therapeutics

CONSULTANT: AbbVie, Adaptive Biotechnologies, AstraZeneca, BeiGene, Eli Lilly

CONSULTING: AbbVie, Adaptive Biotechnologies, AstraZeneca, BeiGene, Bristol Myers Squibb, Celgene, Eli Lilly, Genentech, Janssen, Merck, Research to Practice, TG Therapeutics

GRANT/RESEARCH SUPPORT: AbbVie, Ascentage Pharma, AstraZeneca, Novartis, Surface Oncology, TG Therapeutics

RESEARCH FUNDING: AbbVie, Ascentage Pharma, AstraZeneca, Bristol Myers Squibb, Genentech/Roche, Novartis; Surface Oncology, TG Therapeutics

## **Angela Dispenzieri, MD**

CLINICAL TRIALS: Alnylam; Bristol Myers Squibb; Pfizer, Inc.; Takeda

DATA MONITORING SAFETY COMMITTEE: Oncopeptides; Sorrento

GRANT/RESEARCH SUPPORT: Janssen

INDEPENDENT REVIEW COMMITTEE: Janssen

## **Irene M. Ghobrial, MD**

ADVISORY BOARD: Amgen; Celgene; GSK (GlaxoSmithKline Group); Janssen; Oncopeptides; Pfizer, Inc.; Sanofi; Takeda

CONSULTANT: AbbVie, Adaptive, Amgen, Bristol Myers Squibb, GSK (GlaxoSmithKline Group); Janssen; Karyopharm Therapeutics; Menarini Silicon Biosystems; Oncopeptides; Pfizer, Inc.; Sanofi; Takeda

SPEAKER: Adaptive; Amgen; Bristol Myers Squibb; GSK (GlaxoSmithKline Group); Janssen; Pfizer, Inc.; Sanofi; Takeda

OTHER FINANCIAL OR MATERIAL SUPPORT: Disc Medicine

## **Nilanjan Ghosh, MD, PhD**

CONSULTING OR ADVISORY ROLE: AbbVie, Adaptive Biotechnologies, ADCT Therapeutics, AstraZeneca, BeiGene, Bristol Myers Squibb/Celgene, Genentech/Roche, Genmab, Gilead Sciences, Incyte; Janssen/Pharmacicyclics LLC (an AbbVie company), Karyopharm Therapeutics, Loxo Oncology, Novartis, Seattle Genetics, TG Therapeutics

RESEARCH FUNDING: AbbVie; Bristol Myers Squibb/Celgene; Genentech/Roche; MorphoSys US, Inc.; TG Therapeutics

## **Michael R. Green, PhD**

CONSULTANT: Daiichi Sankyo

RESEARCH FUNDING: Allogene, Kite/Gilead, Sanofi

## **Alex Herrera, MD**

CONSULTANT: ADCT Therapeutics, AstraZeneca, Bristol Myers Squibb, Genentech/Roche, Genmab, Karyopharm Therapeutics, Merck Pharmaceuticals, Regeneron, Seattle Genetics, Takeda

GRANT/RESEARCH SUPPORT: ADCT Therapeutics, AstraZeneca, Genentech/Roche, Gilead Sciences, Kite Pharma, Merck Pharmaceuticals, Seattle Genetics

RESEARCH FUNDING: ADCT Therapeutics, AstraZeneca, Bristol Myers Squibb, Genentech/Roche, Gilead Sciences, Kite Pharma, Merck Pharmaceuticals, Seattle Genetics

.....

**Steven M. Horwitz, MD**

CONSULTING: Kiowa-Kirin, ONO Pharmaceuticals, Seattle Genetics, SecureBio, Takeda, Yingli Pharma Limited  
GRANT SUPPORT: Kyowa Hakko Kirin Co., Ltd.  
RESEARCH SUPPORT: Affimed, Daiichi Sankyo, Seattle Genetics, SecuraBio

**Caron A. Jacobson, MD, MMSc**

CONSULTANT: Bristol Myers Squibb/Celgene, Ipsen, Kite/Gilead, Novartis Pharmaceuticals

**Brad S. Kahl, MD**

CONSULTANT: AbbVie; Acerta/AstraZeneca; ADCT Therapeutics; BeiGene; Celgene; Epizyme, Inc.; Genentech/Roche; Pharmacyclics LLC (an AbbVie company); TG Therapeutics  
RESEARCH SUPPORT: ADCT Therapeutics

**Scott Koepsell, MD, PhD**

ADVISORY BOARD: AstraZeneca/Alexion  
RESEARCH SUPPORT: Werfen

**David S. Kroll, MD**

CONSULTING: AbbVie, Bristol Myers Squibb

**David M. Kurtz, MD, PhD**

STOCK OWNERSHIP, CONSULTING: Foresight Diagnostics

**Ann S. LaCasce, MD, MMSc**

SPEAKERS BUREAU: Research to Practice

**John P. Leonard, MD**

CONSULTANT: Second Genome

**Frederick L. Locke, MD**

SCIENTIFIC ADVISORY ROLE: Allogene, Bluebird Bio, Bristol Myers Squibb/Celgene, Calibr, Caribou, Cellular Biomedicine Group, Daiichi Sankyo, GammaDelta Therapeutics, Iovance, Janssen, Kite Pharma, Legend Biotech, Novartis, Sana, Takeda, Wugen, Umoja  
CONSULTING: Cowen, EcoR1, Emerging Therapy Solutions, Gerson Lehrman Group (GLG)  
RESEARCH FUNDING: Leukemia and Lymphoma Society, National Cancer Institute  
INSTITUTIONAL RESEARCH FUNDING: Allogene, Bluebird Bio, Bristol Myers Squibb, Kite Pharma, Novartis  
EDUCATION OR EDITORIAL: Aptitude Health, ASH, BioPharma Communications, CARE Education, Clinical Care Options Oncology, Imedex, Society for Immunotherapy of Cancer

**Matthew A. Lunning, DO, FACP**

CONSULTANT: AbbVie; Acrotech Biopharma; ADC Therapeutics; Acerta/AstraZeneca; Bristol Myers Squibb; Daiichi Sankyo; EUSA Pharma; Genentech/Roche; Genmab; IstilBio; Kite; MorphoSys US, Inc.; Novartis; TG Therapeutics

**Anthony R. Mato, MD, MSCE**

CONSULTING FEES: AbbVie, Adaptive Biotechnologies, Celgene, DTRM Biopharma, Genentech/Roche, Janssen; Loxo Oncology, Pharmacyclics LLC (an AbbVie company), TG Therapeutics  
CONSULTING FOR CME: Dava, Medscape, Peerview, Vaniam  
CONTRACTED RESEARCH: AbbVie, Adaptive Biotechnologies, Genentech/Roche, Genmab, Janssen, Loxo Oncology, Nurix, Pharmacyclics LLC (an AbbVie company), TG Therapeutics  
RESEARCH/CONSULTING: AbbVie; Adaptive Biotechnologies; BeiGene; DTRM Biopharma; Genentech/Roche; Genmab; Janssen; Loxo Oncology; Nurix; Octopharma; Pharmacyclics LLC (an AbbVie company), TG Therapeutics

**Neha Mehta-Shah, MD, MSCl**

ADVISORY BOARD: C4 Therapeutics, Daiichi-Sankyo, Karyopharm Therapeutics, Kiowa Hakka Kirin, ONO Pharmaceuticals, SecuraBio  
CONSULTANT: C4 Therapeutics, Daiichi-Sankyo, Karyopharm Therapeutics, Kiowa Hakka Kirin, SecuraBio  
GRANT/RESEARCH SUPPORT: AstraZeneca, Bristol Myers Squibb/Celgene, Corvus Pharma, Daiichi-Sankyo, Genentech/Roche, Innate, SecuraBio  
INSTITUTIONAL RESEARCH FUNDING: AstraZeneca, Bristol Myers Squibb/Celgene, C4 Therapeutics, Daiichi-Sankyo, Corvus Pharma, Genentech/Roche; Innate, SecuraBio, Verastem

**Alison J. Moskowitz, MD**

CONSULTANT: Affimed, Imbrium Therapeutics L.P., Merck, Takeda Pharmaceuticals  
CONSULTING: Janpix Ltd., miRagen, Seattle Genetics  
GRANT/RESEARCH SUPPORT: ADC Therapeutics, Bristol Myers Squibb, Merck, miRagen  
RESEARCH SUPPORT: BeiGene, Bristol Myers Squibb, Incyte Corp., Merck, Seattle Genetics, SecuraBio

**Sudipto Mukherjee, MD, PhD, MPH**

RESEARCH CONSULTANCY: Bristol Myers Squibb  
RESEARCH FUNDING (1 investigator-initiated non-therapeutic study): Bristol Myers Squibb/Celgene; (3 investigator-initiated clinical trials) Jazz Pharmaceuticals

# DISCLOSURE INFORMATION

---

## Loretta J. Nastoupil, MD

HONORARIUM: Genentech/Roche, Genmab

## Tyrel Jovelle Phillips, MD

ADVISORY BOARD: AbbVie, Acerta/AstraZeneca, Bayer, BeiGene, Bristol Myers Squibb/Celgene, Epizyme, Genentech/Roche, Gilead Sciences, Incyte, Eli Lilly, Pharmacyclics LLC (an AbbVie company)

RESEARCH FUNDING: AbbVie, Bayer, Bristol Myers Squibb/Celgene, Genentech/Roche, Gilead Sciences, Incyte

STRATEGIC COUNSEL: Epizyme

## Lisa M. Rimsza, MD

CONSULTING: Roche

## Craig S. Sauter, MD

SRC MEMBER: ONO Pharmaceuticals

## David W. Scott, MBChB, PhD

CONSULTANT: Janssen

CONSULTING: AstraZeneca

RESEARCH FUNDING: Genentech/Roche, Janssen, Nanostring Tech

## Laurie H. Sehn, MD, MPH

CONSULTANT: AbbVie, Acerta/AstraZeneca, Celgene, Gilead, Incyte, Janssen, Kite, Merck Pharmaceuticals, Roche/Genentech

INSTITUTIONAL RESEARCH FUNDING: Genentech/Roche, Pharmacyclics LLC (an AbbVie company), Seattle Genetics, Teva, TG Therapeutics

## Nina Shah, MD

CONSULTANT/ADVISORY ROLE: Amgen, Bristol Myers Squibb, Genentech/Roche, GSK, Indapta Therapeutics, Nektar, Precision Biosciences, Sanofi, Surface Oncology

GRANT/RESEARCH SUPPORT: Bluebird Bio, Celgene, Janssen, Sutro Biopharma, Teneobio

RESEARCH FUNDING: Bluebird Bio, Celgene, Janssen, Sutro Biopharma, Teneobio

## Julie M. Vose, MD, MBA

ADVISORY BOARD: AstraZeneca, Genentech/Roche

CONSULTING/HONORARIUM: AbbVie

CONSULTANT: AstraZeneca, Daiichi Sankyo, Genentech/Roche, Johnson & Johnson, Eli Lilly, MEI Pharma

RESEARCH GRANT SUPPORT: Bristol Myers Squibb, Janssen, Pharmacyclics LLC (an AbbVie company)

## Jason R. Westin, MD, MS, FACP

CLINICAL RESEARCH FUNDING: AstraZeneca; Bristol Myers Squibb; Genentech/Roche; Gilead Sciences; MorphoSys US, Inc.; Novartis

CONSULTING: ADC Therapeutics, AstraZeneca; Bristol Myers Squibb; Genentech/Roche; Gilead Sciences; Iksuda; MorphoSys US, Inc.; Novartis; Umoja

## Ashley Wysong, MD, MS

INSTITUTIONAL RESEARCH GRANT: Castle Biosciences

## Jasmine M. Zain, MD

ADVISORY BOARD: Acrotech, Affimed, Daiichi Sankyo, Seattle Genetics

CONSULTANT: Acrotech, Affimed, Daiichi Sankyo, Seattle Genetics

SPEAKERS BUREAU: Acrotech; Kyowa Hakko Kirin Co., Ltd.; Seattle Genetics

## Andrew D. Zelenetz, MD, PhD

CONSULTANT: AbbVie; Adaptive Biotechnology; AstraZeneca; BeiGene; Bristol Myers Squibb; Celgene; Genentech/Roche; Gilead/Kite; Janssen; MEI Pharma; MorphoSys US, Inc.; Novartis

DMC MEMBER: Bristol Myers Squibb, Celgene, Juno

RESEARCH: BeiGene, Bristol Myers Squibb, Genentech/Roche, MEI Pharma

## Andrea J. Zimmer, MD, FACP

INSTITUTIONAL RESEARCH FUNDING: AlloVir

## THE FOLLOWING FACULTY MEMBERS HAVE DISCLOSED OFF-LABEL, EXPERIMENTAL OR INVESTIGATIONAL USE OF DRUGS

### Joshua Brody, MD

Off-label Use: DC mobilization - CDX-301

Off-label Use: DC activation - Hiltonol / polyICLC

### Elizabeth S. Constance, MD, FCOG

Off-label Use: Estradiol suppression during ovarian stimulation for patients with breast cancer - Letrozole

Off-label Use: Ovarian suppression for fertility preservation - Leuprolide Acetate

### Matthew S. Davids, MD, MMSc

Off-label Use: Richter syndrome - Ibrutinib

Off-label Use: Richter syndrome - Venetoclax

### Jonathan W. Friedberg, MD, MMSc

Off-label Use: Lymphomas - Novel therapies



Frederick L. Locke, MD

Off-label Use: Clinical Trials - Axicabtagene Ciloleuce

Anthony R. Mato, MD, MSCE

Off-label Use: CLL - Loxo 305

Neha Mehta-Shah, MD, MSCI

Off-label Use: PTCL - Duvelisib

Sudipto Mukherjee, MD, PhD, MPH

Off-label Use: Studies reporting on use of this drug in iMCD - Ruxolitinib

Off-label Use: Studies reporting on use of this drug in iMCD - Sirolimus

Tycel Jovelle Phillips, MD

Off-label Use: Frontline MCL - Acalabrutinib

Off-label Use: Frontline MCL - Brexucabtagene Autoleuce

Off-label Use: Frontline MCL - Epcoritamab

Off-label Use: Frontline MCL - Ibrutinib

Off-label Use: Frontline MCL - Lenalidomide

Off-label Use: Frontline MCL - Mosunetuzumab/Glofitamab

Off-label Use: Frontline MCL - Zanubrutinib

Craig S. Sauter, MD

Off-label Use: Relapsed and refractory - Ibrutinib

David W. Scott, MBChB, PhD

Off-label Use: DLBCL - Ibrutinib

Off-label Use: DLBCL - Lenalidomide

Nina Shah, MD

Off-label Use: Myeloma - T cell engagers

Ashley Wysong, MD, MS

Off-label Use: CTCL - Topical Steroids

Jasmine M. Zain, MD

Off-label Use: Therapeutic - Duvelisib

Off-label Use: Therapy - Valemetostat

Andrew D. Zelenetz, MD, PhD

Off-label Use: Treatment of B cell lymphoma - BiTES - Bispecific T cell Engager

Andrea J. Zimmer, MD, FACP

Off-label Use: Anti-fungal prophylaxis - Isavuconazole

Off-label Use: Anti-fungal prophylaxis - Voriconazole

**THE FOLLOWING FACULTY MEMBERS HAVE NO RELEVANT FINANCIAL RELATIONSHIPS TO DISCLOSE:**

Joshua Brody, MD

Richard I. Fisher, MD

Theresa Franco, MSN, RN

Jonathan W. Friedberg, MD, MMSc

Jeffrey P. Gold, MD

Craig M. Johnson, MD

Avyakta Kallam, MBBS

Christopher J. Kratochvil, MD

Jared E. Matya, PharmD, BCOP

Craig H. Moskowitz, MD

Rachael L. Schmidt, DNP, FNP-C, AOCNP®

Kim Schmit-Pokorny, RN, MSN, OCN, BMTCN

Bradly Vlcek, BSN, RN, OCN

**THE FOLLOWING PLANNING COMMITTEE MEMBERS HAVE RELEVANT FINANCIAL RELATIONSHIPS TO DISCLOSE:**

James O. Armitage, MD<sup>■</sup>

Matthew W. Lunning, DO, FACP<sup>■</sup>

Julie M. Vose, MD, MBA<sup>■</sup>

**THE FOLLOWING PLANNING COMMITTEE MEMBERS HAVE NO RELEVANT FINANCIAL RELATIONSHIPS TO DISCLOSE:**

Jared E. Matya, PharmD, BCOP

Renee Paulin, MSN, RN, CWOCN

Brenda Ram, CMP, CHCP

<sup>■</sup> Relevant financial relationships noted (see pages 14-16)

# E-POSTERS

## CASE STUDY OF DIFFUSE LARGE B CELL LYMPHOMA PRESENTING WITH OBSTRUCTIVE JAUNDICE

Anisa Suraya Ab Razak, Imperial College School of Medicine MBBS, London, England, United Kingdom

## CUTANEOUS EPSTEIN-BARR-VIRUS-POSITIVE LARGE CELL LYMPHOMA WITH PLASMACYTIC DIFFERENTIATION IN PATIENT WITH TRISOMY 21: A CASE REPORT

Tiba Al Sagheer, PharmD, BCOP<sup>1</sup>, BCACP; Lazaros Lekakis, M.D.<sup>2</sup>; M; Elaine S. Jaffe, M.D.<sup>3</sup>; Manuel Menes, M.D.<sup>1</sup>; Adrienne E. Moul M.D.<sup>1</sup>; Yuliya P.L. Linhares, M.D.<sup>1</sup>, <sup>1</sup>Miami Cancer Institute, Baptist Health South Florida - Miami, FL USA, <sup>2</sup>University of Miami - Sylvester Comprehensive Cancer Center - Miami, FL USA, <sup>3</sup>National Institutes of Health - National Cancer Institute - Bethesda, MD USA

## NODAL INVOLVEMENT IN CUTANEOUS T CELL LYMPHOMA: A RETROSPECTIVE SINGLE CENTER ANALYSIS

Aseala Abousaud, PharmD, BCOP; Pamela Allen, MD; Emory Winship Cancer Institute, Atlanta, GA USA

## SEQUENTIAL PEMBROLIZUMAB AND CHEMOTHERAPY IN NEWLY DIAGNOSED EARLY UNFAVORABLE OR ADVANCED-STAGE CLASSICAL HODGKIN LYMPHOMA (CHL): THE PHASE 2 KEYNOTE-C11 STUDY

Jane N. Winter<sup>1</sup>; Amos Odeleye-Ajakaye<sup>2</sup>; Uzor C. Ogbu<sup>2</sup>; Akash Nahar<sup>2</sup>; Ranjana H. Advani<sup>3</sup>; <sup>1</sup>Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL USA; <sup>2</sup>Merck & Co., Inc., Kenilworth, NJ USA; <sup>3</sup>Stanford Cancer Institute, Stanford, CA USA

## VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 5-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY

Othman Al-Sawaf<sup>1,2,3</sup>, Can Zhang<sup>1</sup>, Sandra Robrecht<sup>1</sup>, Alex Kotak<sup>4</sup>, Naomi Chang<sup>4</sup>, Anna-Maria Fink<sup>1</sup>, Eugen Tausch<sup>5</sup>, Christof Schneider<sup>5</sup>, Matthias Ritgen<sup>6</sup>, Karl-Anton Kreuzer<sup>1</sup>, Brenda Chyla<sup>7</sup>, Barbara Eichhorst<sup>1</sup>, Stephan Stilgenbauer<sup>5</sup>, Yanwen Jiang<sup>8</sup>, Michael Hallek<sup>1</sup>, Kirsten Fischer<sup>1</sup>, <sup>1</sup>Department I of Internal Medicine and Center of Integrated Oncology Aachen Cologne Bonn Duesseldorf, University Hospital of Cologne, Cologne, Germany, <sup>2</sup>Cancer Institute, University College London, <sup>3</sup>Francis Crick Institute, London, <sup>4</sup>Roche Products Ltd, Welwyn Garden City, United Kingdom, <sup>5</sup>Department III of Internal Medicine, Ulm University, Ulm, <sup>6</sup>Department II of Internal Medicine, University of Schleswig Holstein, Kiel, Germany, <sup>7</sup>AbbVie Inc., North Chicago, IL, <sup>8</sup>Genentech Inc., South San Francisco, CA

## BRUIN MCL-321, A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VERSUS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED, BTK INHIBITOR NAÏVE MANTLE CELL LYMPHOMA (TRIAL IN PROGRESS)

M. Balbas<sup>1</sup>, T. Eyre<sup>2</sup>, N. Shah<sup>3</sup>, S. Le Gouill<sup>4</sup>, M. Dreyling<sup>5</sup>, E. Vandenberghe<sup>6</sup>, W. Jurczak<sup>7</sup>, Y. Wang<sup>8</sup>, C. Cheah<sup>9</sup>, M. Gandhi<sup>10</sup>, C. Chay<sup>11</sup>, J. Sharman<sup>12</sup>, D. Andorsky<sup>13</sup>, M. Yin<sup>1</sup>, J. Kherani<sup>1</sup>, M. Wang<sup>14</sup>, <sup>1</sup>Loxo Oncology at Lilly, Stamford, Connecticut, USA; <sup>2</sup>Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, Oxford, UK; <sup>3</sup>Medical College of Wisconsin, Milwaukee, USA; <sup>4</sup>Service d'hématologie clinique du CHU de Nantes, INSERM CRCINA Nantes-Angers, NeXT Université de Nantes, Nantes, France; <sup>5</sup>Department of Medicine III, LMU University Hospital, Munich, Germany; <sup>6</sup>Hope Directorate St. James Hospital, Dublin, Ireland; <sup>7</sup>Maria Skłodowska-Curie National Research Institute of Oncology, Krakow, Poland; <sup>8</sup>Division of Hematology, Mayo Clinic, Rochester, MN, USA; <sup>9</sup>Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia; <sup>10</sup>Virginia Cancer Specialists, Fairfax, VA, USA; <sup>11</sup>Messino Cancer Centers, Asheville, NC, USA; <sup>12</sup>Willamette Valley Cancer Institute and Research Center, US Oncology Research, Eugene, OR, USA; <sup>13</sup>Rocky Mountain Cancer Centers, US Oncology Research, Boulder, CO; <sup>14</sup>University of Texas MD Anderson Cancer Center, Houston, USA

## BRUIN CLL-313: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VERSUS BENDAMUSTINE PLUS RITUXIMAB IN UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (TRIAL IN PROGRESS)

K. Bao<sup>1</sup>, W. Jurczak<sup>2</sup>, C. Dartigeas<sup>3</sup>, M. Coscia<sup>4</sup>, P. Ganly<sup>5</sup>, G. Al-Jazayry<sup>6</sup>, C. Wang<sup>7</sup>, C. Leow<sup>1</sup>, S. Shahda<sup>1</sup>, P. Zinzani<sup>8</sup>, <sup>1</sup>Loxo Oncology at Lilly, Stamford, CT, USA; <sup>2</sup>Maria Skłodowska-Curie National Research Institute of Oncology, Krakow, Poland; <sup>3</sup>Centre Hospitalier Universitaire de Tours, Hôpital Bretonneau, Tours, France; <sup>4</sup>Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Italy; <sup>5</sup>Christchurch Hospital, Christchurch, NZ; <sup>6</sup>Hollywood Presbyterian Medical Tower, Los Angeles, CA, USA; <sup>7</sup>Eli Lilly and Company, Indianapolis, IN, USA; <sup>8</sup>Institute of Hematology "Seràgnoli" University of Bologna, Bologna Italy

## PHARMACOKINETICS AND PHARMACODYNAMICS IN FIRST-MIND: A PHASE IB, OPEN-LABEL, RANDOMIZED STUDY OF TAFASITAMAB ± LENALIDOMIDE+ R-CHOP IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA

David Belada<sup>1</sup>, Katerina Kopeckova<sup>2</sup>, Juan Miguel Bergua Burgues<sup>3</sup>, Don Stevens<sup>4</sup>, Grzegorz S. Nowakowski<sup>5</sup>, Maeve Waldron-Lynch<sup>6</sup>, Nira Hadar<sup>6</sup>, Johannes Weirather<sup>7</sup>, Charlotte Lässig<sup>7</sup>, Derek Blair<sup>7</sup>, Martin Dreyling<sup>8</sup>, <sup>1</sup>4<sup>th</sup> Department of Internal Medicine - Haematology, Charles University, Hospital and Faculty of Medicine, Hradec Králové, Czech Republic; <sup>2</sup>Department of Oncology of the 2<sup>nd</sup> Faculty of Medicine of Charles University and University Hospital in Motol, Prague, Czech Republic; <sup>3</sup>Department of Hematology, Hospital San Pedro de Alcántara, Cáceres, Spain; <sup>4</sup>Norton Cancer Institute - St. Matthews Campus, 3991 Dutchmans Lane, 40207 Louisville, Kentucky, USA; <sup>5</sup>Division of Hematology, Mayo Clinic, Rochester, MN, USA; <sup>6</sup>MorphoSys US, Inc., Boston, MA, USA; <sup>7</sup>MorphoSys AG, Planegg, Germany; <sup>8</sup>Medical Clinic III, Ludwig-Maximilians-University Hospital, Munich, Germany

**EPCORITAMAB (EPCO) WITH GEMCITABINE + OXALIPLATIN (GEMOX) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) INELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) INDUCES HIGH RESPONSE RATE EVEN IN PTS FAILING CAR T THERAPY**

Joshua Brody, MD,<sup>1</sup> Björn E. Wahlin, MD, PhD,<sup>2</sup> Tycel Phillips, MD,<sup>3</sup> Régis Costello, MD, PhD,<sup>4</sup> Pietermella Lugtenburg, MD, PhD,<sup>5</sup> Raul Cordoba, MD, PhD,<sup>6</sup> Liwei Wang, PhD,<sup>7</sup> Jun Wu, MD, MS,<sup>8</sup> Brian Elliott, MD,<sup>7</sup> Aqeel Abbas, MS,<sup>7</sup> Judit Jørgensen, MD, PhD<sup>9</sup>, Icahn School of Medicine at Mount Sinai, New York, NY, USA; <sup>2</sup>Karolinska Institutet, Stockholm, Sweden; <sup>3</sup>University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA; <sup>4</sup>Assistance Publique – Hôpitaux de Marseille (AP-HM), Marseille, France; <sup>5</sup>On behalf of the Lunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC, Erasmus MC Cancer Institute, Department of Hematology, Rotterdam, Netherlands; <sup>6</sup>Fundacion Jimenez Diaz University Hospital, Health Research Institute IIS-FJD, Madrid, Spain; <sup>7</sup>Genmab, Princeton, NJ, USA; <sup>8</sup>AbbVie, North Chicago, IL, USA; <sup>9</sup>Aarhus University Hospital, Aarhus, Denmark

**MOSUNETUZUMAB MONOTHERAPY IS AN EFFECTIVE AND WELL-TOLERATED TREATMENT OPTION FOR PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) WHO HAVE RECEIVED ≥2 PRIOR LINES OF THERAPY: PIVOTAL RESULTS FROM A PHASE I/II STUDY**

L E Budde,<sup>1</sup> L H Sehn,<sup>2</sup> M Matasar,<sup>3</sup> S J Schuster,<sup>4</sup> S Assouline,<sup>5</sup> P Giri,<sup>6</sup> J Kuruvilla,<sup>7</sup> M Canales,<sup>8</sup> S Dietrich,<sup>9</sup> K Fay,<sup>10</sup> M Ku,<sup>11</sup> L Nastoupil,<sup>12</sup> M C Wei,<sup>13</sup> S Yin,<sup>13</sup> M Y Doral,<sup>13</sup> C-C Li,<sup>13</sup> H Huang,<sup>14</sup> R Negricea,<sup>15</sup> E Penuel,<sup>13</sup> C O'Hear,<sup>13\*</sup> N L Bartlett<sup>16</sup>, <sup>1</sup>City of Hope, Duarte, CA, USA; <sup>2</sup>BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, BC, Canada; <sup>3</sup>Memorial Sloan Kettering Cancer Center, New York, NY, USA; <sup>4</sup>Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA; <sup>5</sup>Jewish General Hospital, Montreal, QC, Canada; <sup>6</sup>Royal Adelaide Hospital, Adelaide, Australia; <sup>7</sup>Princess Margaret Cancer Centre, Toronto, ON, Canada; <sup>8</sup>Hospital Universitario La Paz, Madrid, Spain; <sup>9</sup>Universität Heidelberg, Heidelberg, Germany; <sup>10</sup>St Vincent's Hospital and Royal North Shore Hospital, Sydney, Australia; <sup>11</sup>St Vincent's Hospital, University of Melbourne, Melbourne, Australia; <sup>12</sup>MD Anderson Cancer Center, Houston, TX, USA; <sup>13</sup>Genentech, Inc., South San Francisco, CA, USA; <sup>14</sup>F. Hoffmann-La Roche Ltd, Mississauga, ON, Canada; <sup>15</sup>Roche Products Ltd, Welwyn Garden City, United Kingdom; <sup>16</sup>Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA  
\*Currently: Gilead Sciences, Inc., Foster City, CA, USA

**A SEER-MEDICARE ANALYSIS OF THE COST OF DISEASE PROGRESSION AFTER FRONTLINE (1L) R-CHOP IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)**

John M. Burke,<sup>1</sup> Rongrong Wang,<sup>2</sup> Farah Hossain,<sup>2</sup> Jia Li,<sup>2</sup> Anthony Masaquel,<sup>2</sup> Summera Qiheng Zhou,<sup>3</sup> Matthew Matasar<sup>4</sup>, <sup>1</sup>Rocky Mountain Cancer Centers/US Oncology, Aurora, CO, USA; <sup>2</sup>Genentech Inc., South San Francisco, CA, USA; <sup>3</sup>Genesis Research, Hoboken, NJ, USA; <sup>4</sup>Memorial Sloan Kettering Cancer Center, New York, NY, USA

**Congratulations to our  
2022 PPLC Abstract  
Travel Stipend Recipients**

Hua-Jay J. Cherng, MD

The University of Texas MD Anderson Cancer Center  
Houston, TX

Karan L. Chohan, MD

Mayo Clinic  
Rochester, MN

Daniel K. Ebner, MD, MPH

Mayo Clinic  
Rochester, MN

Swetha Kambhampati, MD

City of Hope National Medical Center  
Duarte, CA

Adrienne Maurer, MSN, RN, AG-ACNP, BMTCN

Seattle Cancer Care Alliance, Fred Hutchinson Cancer Center  
University of Washington  
Seattle, WA

Karmila Murphy, APRN

The University of Texas MD Anderson Cancer Center  
Houston, TX

# E-POSTERS

## **AN ANALYSIS OF PATIENTS ≥65 YEARS WITH BURKITT LYMPHOMA (BL) IN THE RITUXIMAB ERA: SURVIVAL TRENDS, TREATMENT PATTERNS, AND SECONDARY CAUSES OF DEATH**

Ethan A. Burns<sup>1</sup>, Sunil Mathur<sup>1</sup>, Justin Wilson<sup>2</sup>, Zimu Gong<sup>1</sup>, Ryan Kieser<sup>1</sup>, Jenny Petkova<sup>3</sup>, Lawrence Rice<sup>2</sup>, Shilpan Shah<sup>1</sup>, Siddhartha Ganguly<sup>1</sup>, Sai Ravi Pingali<sup>1</sup>, <sup>1</sup>Houston Methodist Cancer Center, 6445 Main St Floor 24, Houston, TX 77030, USA, <sup>2</sup>Trinity School of Medicine, 925 Woodstock Road, Suite 200, Roswell, GA 30075, USA, <sup>3</sup>Houston Methodist Hospital, Department of Medicine, 6550 Fannin St, Houston, TX, 77030

## **WAVELINE-004: PHASE 2 STUDY OF ZILOVERTAMAB VEDOTIN MONOTHERAPY FOR RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA**

Pier Luigi Zinzani,<sup>1,2</sup> Kumudu Pathiraja,<sup>3</sup> Samhita Chakraborty,<sup>3</sup> Akash Nahar,<sup>3</sup> Mitchell Cairo<sup>4</sup>, <sup>1</sup>IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia "Seragnoli", Bologna, Italy, <sup>2</sup>Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy, <sup>3</sup>Merck & Co., Inc., Kenilworth, NJ, USA, <sup>4</sup>Westchester Medical Center, New York Medical College, Valhalla, NY, USA

## **WAVELINE-003: OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF ZILOVERTAMAB VEDOTIN PLUS STANDARD OF CARE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA**

Patrick Cobb<sup>1</sup>; Heng Zhou<sup>2</sup>; Samhita Chakraborty<sup>2</sup>; Akash Nahar<sup>2</sup>, <sup>1</sup>St. Vincent Healthcare Cancer Centers of Montana, Billings MT, USA; <sup>2</sup>Merck & Co., Inc., Kenilworth, NJ, USA

## **POSITRON EMISSION TOMOGRAPHY DERIVED METRICS IN RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA WITH RESIDUAL DISEASE BEFORE AUTOLOGOUS STEM CELL TRANSPLANT**

Hua-Jay J. Cherng, Guofan Xu, Lei Feng, Raphael Steiner, Luis Fayad, Paolo Strati, Ranjit Nair, Loretta J. Nastoupil, Hun Ju Lee, Sattva S. Neelapu, Christopher R. Flowers, Maria Rodriguez, Jeremy Ramdial, Samer Srour, Yago Nieto, Richard Champlin, Jason Westin, Homer Macapinlac, Elizabeth Shpall\*, Sairah Ahmed\* (\*=contributed equally) - The University of Texas MD Anderson Cancer Center, Houston, TX

## **A REAL-WORLD STUDY OF COMBINED MODALITY THERAPY FOR EARLY-STAGE HODGKIN LYMPHOMA IN THE PET ERA: TOO LITTLE TREATMENT IMPACTS OUTCOME**

Karan L. Chohan, MD<sup>1</sup>; Jason R. Young, MD<sup>2</sup>; Scott Lester, MD<sup>3</sup>; Muhamad Alhaj Moustafa, MD<sup>4</sup>; Allison Rosenthal, DO<sup>5</sup>; Han W. Tun, MD<sup>4</sup>; Bradford S. Hoppe, MD, MPH<sup>6</sup>; Patrick B. Johnston, MD, PhD<sup>7</sup>; Ivana N. Micallef, MD<sup>7</sup>; Thomas M. Habermann, MD<sup>7</sup>; Stephen M. Ansell, MD, PhD<sup>7</sup>, <sup>1</sup>Department of Medicine, Mayo Clinic, Rochester, MN, USA; <sup>2</sup>Department of Radiology, Mayo Clinic, Jacksonville, FL; <sup>3</sup>Department of Radiation Oncology, Mayo Clinic, Rochester, MN; <sup>4</sup>Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL; <sup>5</sup>Division of Hematology, Mayo Clinic, Phoenix, AZ; <sup>6</sup>Department of Radiation Oncology, Jacksonville, FL; <sup>7</sup>Division of Hematology, Mayo Clinic, Rochester, MN.

## **OUTCOMES OF LYMPHOMA PATIENTS WITH COVID INFECTION DURING OMICRON SURGE**

Alexandra Della Pia,<sup>1,2</sup> Gee Youn (Geeny) Kim,<sup>1,2</sup> Andrew Ip,<sup>1,4,5</sup> Jaeil Ahn,<sup>3</sup> Yanzhi Liu,<sup>3</sup> Michael Koropsak,<sup>1,4</sup> Charles Zhao,<sup>5</sup> Amolika Gupta,<sup>5</sup> Mark Batistick,<sup>5</sup> Gabriella Magarelli<sup>1</sup>, Brittany Lukaski<sup>1</sup>, Lori A. Leslie,<sup>1,4,5</sup> Andre Goy,<sup>1,4,5</sup> Tatyana Feldman<sup>1,4,5</sup>, <sup>1</sup>Hackensack University Medical Center, Hackensack, NJ, USA; <sup>2</sup>Ernest Mario School of Pharmacy at Rutgers University, Piscataway, NJ, USA; <sup>3</sup>Department of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University, Washington, DC, USA; <sup>4</sup>John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA; <sup>5</sup>Hackensack Meridian School of Medicine, Nutley, NJ, USA

## **ASPEN: LONG-TERM FOLLOW-UP RESULTS OF A PHASE 3 RANDOMIZED TRIAL OF ZANUBRUTINIB (ZANU) VS IBRUTINIB (IBR) IN PATIENTS (PTS) WITH WALDENSTRÖM MACROGLOBULINEMIA (WM)**

Meletios Dimopoulos, MD<sup>1</sup> Stephen Opat, MBBS<sup>2</sup> Shirley D'Sa, MD<sup>3</sup> Wojciech Jurczak, MD<sup>4</sup> Hui-Peng Lee, MBChB<sup>5</sup> Gavin Cull, MBBS<sup>6</sup> Roger G. Owen, MD<sup>7</sup> Paula Marlton, MBBS<sup>8</sup> Bjorn E. Wahlin, MD, PhD<sup>9</sup> Ramon Garcia-Sanz, MD, PhD<sup>10</sup> Helen McCarthy, MD<sup>11</sup> Stephen Mulligan, MBBS, PhD<sup>12</sup> Alessandra Tedeschi, MD<sup>13</sup> Jorge J. Castillo, MD<sup>14</sup> Jaroslaw Czyz, MD, PhD<sup>15</sup> Carlos Fernandez De Larrea Rodriguez, MD, PhD<sup>16</sup> David Belada, PhD<sup>17</sup> Edward Libby, MD<sup>18</sup> Jeffrey Matous, MD<sup>19</sup> Marina Motta, MD<sup>20</sup> Tanya Siddiqi, MD<sup>21</sup> Monica Tani, MD<sup>22</sup> Marek Trnny, MD<sup>23</sup> Monique Minnema, MD, PhD<sup>24</sup> Christian Buske, MD<sup>25</sup> Veronique Leblond, MD, PhD<sup>26</sup> Steven P. Treon, MD, PhD<sup>14</sup> Judith Trotman, MBChB<sup>27</sup> Wai Y. Chan, DPhil<sup>28</sup> Jingjing Schneider, PhD<sup>28</sup> Heather Allowelt, MD<sup>28</sup> Sheel Patel, PharmD<sup>28</sup> Aileen Cohen, MD<sup>28</sup> Constantine S. Tam, MD<sup>29</sup>, <sup>1</sup>National and Kapodistrian University of Athens, Athens, Greece <sup>2</sup>Monash Health & Monash University, Clayton, Victoria, AUS <sup>3</sup>Centre for Waldenström's Macroglobulinemia & Associated Disorders, University College London Hospital Foundation Trust, London, United Kingdom <sup>4</sup>Maria Sklodowska-Curie National Institute of Oncology, Krakow, Poland <sup>5</sup>Flinders Medical Centre, Adelaide, SA, AUS <sup>6</sup>Sir Charles Gairdner Hospital, University of Western Australia, Perth, WA, AUS <sup>7</sup>St James University Hospital, Leeds, United Kingdom <sup>8</sup>Princess Alexandra Hospital, University of Queensland, Brisbane, Queensland, AUS <sup>9</sup>Karolinska Universitetssjukhuset & Karolinska Institutet, Stockholm, Sweden <sup>10</sup>Hospital Universitario de Salamanca, Salamanca, Spain <sup>11</sup>Royal Bournemouth & Christchurch Hospital, Bournemouth, United Kingdom <sup>12</sup>Royal North Shore Hospital, Sydney, New South Wales, AUS <sup>13</sup>ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy <sup>14</sup>Dana-Farber Cancer Institute, Boston, MA, USA <sup>15</sup>Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Bydgoszcz, Poland <sup>16</sup>Hospital Clínic de Barcelona, Barcelona, Spain <sup>17</sup>FN Hradec Kralove, Hradec Králové, Czechia <sup>18</sup>University of Washington/Seattle Cancer Care Alliance - Clinical Research, Seattle, WA, USA <sup>19</sup>Colorado Blood Cancer Institute, Denver, Colorado, USA <sup>20</sup>AO Spedali Civili di Brescia, Lombardia, Italy <sup>21</sup>City of Hope National Medical Center, Duarte, CA, USA <sup>22</sup>Ospedale Civile Santa Maria delle Croci, AUSL Ravenna, Italy <sup>23</sup>Všeobecná fakultní nemocnice v Praze, Prague, Czechia <sup>24</sup>University Medical Center Utrecht, Utrecht, Netherlands <sup>25</sup>CCC Ulm - Universitätsklinikum Ulm, Ulm, Baden-Württemberg, Germany <sup>26</sup>Sorbonne University, Pitié Salpêtrière Hospital, Paris, France <sup>27</sup>Concord Repatriation General Hospital, Sydney, New South Wales, AUS <sup>28</sup>BeiGene USA, Inc., San Mateo, CA, USA <sup>29</sup>Royal Melbourne Hospital, Parkville, Victoria, AUS

### **TRANSCRIPTIONAL REGULATION OF AURORA-B KINASE EXPRESSION IN B CELL LYMPHOMA**

S. Dovat<sup>1</sup>, Y. Ding<sup>1</sup>, D. Bogush<sup>1</sup>, A. Sharma<sup>1</sup>, and D. Desai<sup>1</sup>, <sup>1</sup>Penn State University College of Medicine, Hershey, PA, USA

### **DIAGNOSIS AND MANAGEMENT OF IMMUNE-RELATED ADVERSE EVENTS IN RELAPSED FOLLICULAR LYMPHOMA PATIENTS TREATED WITH PEMBROLIZUMAB AND RITUXIMAB IN A PHASE II SINGLE-SITE STUDY AT MD ANDERSON CANCER CENTER**

L.Dsouza<sup>1</sup>, J Thomas<sup>1</sup>, L Nastoupil<sup>1</sup>, <sup>1</sup>MD Anderson Cancer Center Houston, TX United States

### **ANALYSIS OF PROGRESSION FOLLOWING MODERN REDUCED VOLUME, REDUCED DOSE RADIATION THERAPY FOR HODGKIN LYMPHOMA**

Daniel K Ebner MD MPH<sup>1</sup>, William Breen MD<sup>1</sup>, Karan Chohan MD<sup>2</sup>, Bradley Stish MD<sup>1</sup>, Safia Ahmed MD<sup>1</sup>, Anita Mahajan MD<sup>1</sup>, Nadia Laack MD<sup>1</sup>, Thomas M. Habermann, MD<sup>3</sup>, Stephen Ansell MD PhD<sup>3</sup>, Scott Lester MD<sup>1</sup>, <sup>1</sup>Department of Radiation Oncology, Mayo Clinic, Rochester MN, 55905, United States <sup>2</sup>Department of Internal Medicine, Mayo Clinic, Rochester MN, 55905, United States <sup>3</sup>Division of Hematology, Mayo Clinic, Rochester MN, 55905, United States

### **FIRST-LINE TREATMENT (TX) WITH SUBCUTANEOUS (SC) EPCORITAMAB (EPCO) + R-CHOP IN PATIENTS (PTS) WITH HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): PHASE 1/2 DATA UPDATE**

Michael Roost Clausen, MD, PhD,<sup>1</sup> Fritz Offner, MD, PhD,<sup>2</sup> David Belada, MD, PhD,<sup>3</sup> Joshua Brody, MD,<sup>4</sup> Kim M. Linton, MBChB, PhD,<sup>5</sup> Yasmin Karimi, MD,<sup>6</sup> Raul Cordoba, MD, PhD,<sup>7</sup> Sylvia Snauwaert, MD, PhD,<sup>8</sup> Aqeel Abbas, MS,<sup>9</sup> Liwei Wang, PhD,<sup>9</sup> Jun Wu, MD, MS,<sup>10</sup> Brian Elliott, MD,<sup>9</sup> Lorenzo Falchi, MD<sup>11</sup>, <sup>1</sup>Vejle Hospital, Vejle, Denmark; <sup>2</sup>Universitair Ziekenhuis Gent, Ghent, Belgium; <sup>3</sup>4th Department of Internal Medicine – Hematology, University Hospital and Faculty of Medicine, Hradec Králové, Czech Republic; <sup>4</sup>Icahn School of Medicine at Mount Sinai, New York, NY, USA; <sup>5</sup>The Christie NHS Foundation Trust and Manchester Cancer Research Centre, Manchester, UK; <sup>6</sup>University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA; <sup>7</sup>Fundacion Jimenez Diaz University Hospital, Health Research Institute IIS-FJD, Madrid, Spain; <sup>8</sup>Department of Hematology, AZ Sint-Jan Hospital, Bruges, Belgium; <sup>9</sup>Genmab, Princeton, NJ, USA; <sup>10</sup>AbbVie, North Chicago, IL, USA; <sup>11</sup>Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA

### **SUBCUTANEOUS EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R<sup>2</sup>) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): UPDATE FROM PHASE 1/2 TRIAL**

Lorenzo Falchi, MD,<sup>1</sup> Sirpa Leppä, MD,<sup>2</sup> Björn E. Wahlin, MD, PhD,<sup>3</sup> Marcel Nijland, MD, PhD,<sup>4</sup> Jacob Haaber Christensen, MD, PhD,<sup>5</sup> Sven de Vos, MD, PhD,<sup>6</sup> Harald Holte, MD, PhD,<sup>7</sup> Kim M. Linton, MBChB, PhD,<sup>8</sup> Aqeel Abbas, MS,<sup>9</sup> Liwei Wang, PhD,<sup>9</sup> Minh Dinh, MD,<sup>10</sup> Brian Elliott, MD,<sup>9</sup> David Belada, MD, PhD<sup>11</sup>, <sup>1</sup>Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA; <sup>2</sup>Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland; <sup>3</sup>Karolinska Institutet, Stockholm, Sweden; <sup>4</sup>University Medical Center Groningen and University of Groningen, Groningen, Netherlands; <sup>5</sup>Odense University Hospital, Odense, Denmark; <sup>6</sup>Ronald Reagan University of California Los Angeles Medical Center, Los Angeles, CA, USA; <sup>7</sup>Oslo University Hospital and KG Jebsen Center for B-cell Malignancies, Oslo, Norway; <sup>8</sup>The Christie NHS Foundation Trust and Manchester Cancer Research Centre, Manchester, UK; <sup>9</sup>Genmab, Princeton, NJ, USA; <sup>10</sup>AbbVie, North Chicago, IL, USA; <sup>11</sup>4th Department of Internal Medicine – Hematology, University Hospital and Faculty of Medicine, Hradec Králové, Czech Republic

### **QUIZARTINIB PROLONGED SURVIVAL VS PLACEBO PLUS INTENSIVE INDUCTION AND CONSOLIDATION THERAPY FOLLOWED BY SINGLE-AGENT CONTINUATION IN PATIENTS AGED 18-75 YEARS WITH NEWLY DIAGNOSED FLT3-ITD+ AML**

Harry Erba<sup>1</sup>, Pau Montesinos<sup>2</sup>, Radovan Vrhovac<sup>3</sup>, Elzbieta Patkowska<sup>4</sup>, Hee-Je Kim<sup>5</sup>, Pavel Zak<sup>6</sup>, Po-Nan Wang<sup>7</sup>, Tsvetomir Mitov<sup>8</sup>, James Hanyok<sup>9</sup>, Li Liu<sup>9</sup>, Aziz Benzohra<sup>9</sup>, Arnaud Lesegretain<sup>9</sup>, Jorge Cortes<sup>10</sup>, Alexander Perl<sup>11</sup>, Mikkael Sekeres<sup>12</sup>, Hervé Dombret<sup>13</sup>, Sergio Amadori<sup>14</sup>, Jianxiang Wang<sup>15</sup>, Mark Levis<sup>16</sup>, Richard Schlenk<sup>17</sup> <sup>1</sup>Duke Cancer Institute, Durham, NC, United States of America, <sup>2</sup>La Fe University and Polytechnic Hospital, Valencia, Spain, <sup>3</sup>University Hospital Centre Zagreb, Zagreb, Croatia, <sup>4</sup>Institute of Hematology and Blood Transfusion, Warsaw, Poland, <sup>5</sup>Catholic Hematology Hospital, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea, <sup>6</sup>University Hospital Hradec Kralove, Hradec Kralove, Czech Republic, <sup>7</sup>Chang Gung Medical Foundation, Linkou, Taiwan, <sup>8</sup>Daiichi Sankyo UK Ltd, Uxbridge, United Kingdom, <sup>9</sup>Daiichi Sankyo, Inc, Basking Ridge, NJ, United States of America, <sup>10</sup>Augusta University Medical Center, Augusta, GA, United States of America, <sup>11</sup>University of Pennsylvania, Philadelphia, PA, United States of America, <sup>12</sup>University of Miami Health System, Miami, FL, United States of America, <sup>13</sup>Saint Louis Hospital, University of Paris, Paris, France, <sup>14</sup>Tor Vergata Polyclinic Hospital Rome, Rome, Italy, <sup>15</sup>Institute of Hematology and Blood Diseases Hospital, Tianjin, China, <sup>16</sup>Johns Hopkins University, Baltimore, MD, United States of America, <sup>17</sup>Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany

# E-POSTERS

## **ENCORE: CLASSIC HODGKIN LYMPHOMA: REAL-WORLD OBSERVATIONS FROM PHYSICIANS, PATIENTS, AND CAREGIVERS ON THE DISEASE AND ITS TREATMENT (CONNECT): PHYSICIAN FRONTLINE TREATMENT PREFERENCES FOR STAGE III OR IV CLASSIC HODGKIN LYMPHOMA**

Andrew M. Evens<sup>1</sup>; Kristina S. Yu<sup>2</sup>; Nicholas Liu<sup>2</sup>; Andy Surinach<sup>3</sup>; Katie Holmes<sup>4</sup>; Carlos Flores<sup>3</sup>; Supriya Kumar<sup>4</sup>; Michelle Fanale<sup>2</sup>; Darcy R. Flora<sup>5</sup>; Susan K. Parsons<sup>6</sup>, (\* at time of study): <sup>1</sup>Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA; <sup>2</sup>Seagen Inc., Bothell, WA, USA; <sup>3</sup>Genesis Research, Hoboken, NJ, USA; <sup>4</sup>Ipsos Healthcare, New York, NY, USA; <sup>5</sup>GRYT Health, Rochester, NY, USA; <sup>6</sup>Tufts Medical Center, Boston, MA, USA

## **MORNINGSUN: AN OPEN-LABEL, PHASE II TRIAL ASSESSING THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY IN PATIENTS WITH SELECT B-CELL NON-HODGKIN LYMPHOMAS**

I W Flinn<sup>1</sup>; N S Yao<sup>2</sup>; J M L Biondo<sup>2</sup>; M Wu<sup>2</sup>; T Lin<sup>2</sup>; M C Wei<sup>2</sup>; A Kwan<sup>2</sup>; Y Mun<sup>2</sup>; V S Chopra<sup>2</sup>; J M Burke<sup>3</sup>; <sup>1</sup>Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, US; <sup>2</sup>Genentech, Inc., South San Francisco, CA, US; <sup>3</sup>US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, Aurora, CO, USA

## **ENCORE: CLASSIC HODGKIN LYMPHOMA: REAL-WORLD OBSERVATIONS FROM PHYSICIANS, PATIENTS, AND CAREGIVERS ON THE DISEASE AND ITS TREATMENT (CONNECT)—A CROSS-SECTIONAL SURVEY OF PATIENTS WITH STAGE III OR IV CLASSIC HODGKIN LYMPHOMA COMPARED BY AGE**

Darcy R. Flora<sup>1</sup>; Susan K. Parsons<sup>2</sup>; Nicholas Liu<sup>3</sup>; Kristina S. Yu<sup>3</sup>; Katie Holmes<sup>4</sup>; Carlos Flores<sup>5</sup>; Michelle Fanale<sup>3</sup>; Supriya Kumar<sup>4</sup>; Andy Surinach<sup>5</sup>; Rachel Byrd<sup>1</sup>; Andrew M. Evens<sup>6</sup>, (\*at time of study): <sup>1</sup>GRYT Health, Rochester, NY, USA; <sup>2</sup>Tufts Medical Center, Boston, MA, USA; <sup>3</sup>Seagen Inc., Bothell, WA, USA; <sup>4</sup>Ipsos Healthcare, New York, NY, USA; <sup>5</sup>Genesis Research, Hoboken, NJ, USA; <sup>6</sup>Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA

## **REALMIND: A PROSPECTIVE, MULTICENTER, OBSERVATIONAL STUDY OF PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA STARTING SECOND-/THIRD-LINE THERAPY AND NOT RECEIVING A STEM CELL TRANSPLANT**

Christopher R. Flowers<sup>1</sup>; John M. Burke<sup>2</sup>; Mirko Vukcevic<sup>3</sup>; Susan Snodgrass<sup>4</sup>; Kim Saverno<sup>4</sup>; Mary Ann A. Lumiqued<sup>3</sup>; Haifaa Abdulhaq<sup>5</sup>; Elizabeth Brem<sup>6</sup>; Andrew Evens<sup>7</sup>; Umar Farooq<sup>8</sup>; Pierluigi Porcu<sup>9</sup>; Mazyar Shadman<sup>10</sup>; <sup>1</sup>Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; <sup>2</sup>US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, Aurora, Colorado, USA; <sup>3</sup>MorphoSys AG, Planegg, Germany; <sup>4</sup>Incyte Corporation, Wilmington, Delaware, USA; <sup>5</sup>University of California San Francisco, Fresno/Community Cancer Institute, Clovis, California, USA; <sup>6</sup>UCI Health Irvine, Irvine, California, USA; <sup>7</sup>Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA; <sup>8</sup>University of Iowa Hospitals & Clinics, Iowa City, Iowa, USA; <sup>9</sup>Thomas Jefferson University, Philadelphia, Pennsylvania, USA; <sup>10</sup>Fred Hutchinson Cancer Research Center Seattle, Washington, USA

## **MINDWAY: A PHASE IB/II DOSE OPTIMIZATION STUDY TO ASSESS SAFETY AND PHARMACOKINETICS OF TAFASITAMAB + LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA**

Richard Greil<sup>1</sup>; Katerina Kopeckova<sup>2</sup>; Luca Arcaini<sup>3</sup>; Aasim Amin<sup>4</sup>; Katrien de Graaf<sup>4</sup>; Anna-Maria Jegg<sup>4</sup>; <sup>1</sup>Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute – Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Paracelsus Medical University, Salzburg, Austria. Cancer Cluster Salzburg, Austria; <sup>2</sup>Department of Oncology of the 2<sup>nd</sup> Faculty of Medicine of Charles University and Motol University Hospital, Praha, Czech Republic; <sup>3</sup>Division of Hematology, Fondazione IRCCS Policlinico San Matteo and Department of Molecular Medicine, University of Pavia, Pavia, Italy; <sup>4</sup>MorphoSys AG, Planegg, Germany

## **MANAGEMENT OF BISPECIFIC TOXICITY: CYTOKINE RELEASE SYNDROME (CRS) IN NON-HODKINS LYMPHOMA FOR THE ADVANCED PRACTICE PROVIDER (APP)**

M.D. Guerrero DNP, NP-C, AOCNP, MD Anderson Cancer Center, Houston, TX

## **IDENTIFICATION OF THE PATHWAY OF BIA-ALCL BY ANALYZING THE DIFFERENCE IN IMMUNE RESPONSE ACCORDING TO THE TEXTURE OF THE BREAST IMPLANT**

Sanyeowool An<sup>1</sup>; Jeong Hyun Ha<sup>2</sup>; Youngil Koh<sup>3</sup>; Ung Sik Jin<sup>2,4</sup>; Sung-Soo Yoon<sup>3</sup>; <sup>1</sup>Cancer research Institute, Seoul National University College of Medicine, Seoul, Korea; <sup>2</sup>Department of Plastic and Reconstructive Surgery, Seoul National University Hospital, Seoul, Korea; <sup>3</sup>Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea; <sup>4</sup>Department of Plastic and Reconstructive Surgery, Seoul National University College of Medicine, Seoul, Korea

## **BRUIN CLL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VERSUS INVESTIGATOR'S CHOICE OF IDELALISIB PLUS RITUXIMAB OR BENDAMUSTINE PLUS RITUXIMAB IN BTK INHIBITOR PRETREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (TRIAL IN PROGRESS)**

M. Hill<sup>1</sup>; J. Sharman<sup>2</sup>; W. Jurczak<sup>3</sup>; C. Coombs<sup>4</sup>; D. Wang<sup>1</sup>; N. Ku<sup>1</sup>; A. Guntur<sup>1</sup>; S. Shahda<sup>1</sup>; C. Leow<sup>1</sup>; P. Ghia<sup>5</sup>; A. Mato<sup>6</sup>; <sup>1</sup>Loxo Oncology at Lilly, Stamford, CT, USA; <sup>2</sup>Willamette Valley Cancer Institute and Research Center, US Oncology Research, Eugene, OR, USA; <sup>3</sup>Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland; <sup>4</sup>University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; <sup>5</sup>Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy; <sup>6</sup>Memorial Sloan Kettering Cancer Center, New York, NY, USA

### **SUBCUTANEOUS PANNICULITIS-LIKE T-CELL LYMPHOMA: CLINICAL CHARACTERISTICS, THERAPEUTIC APPROACH, AND OUTCOME; A 20-YEAR RETROSPECTIVE CASE SERIES**

Jakrawadee Julamane<sup>1</sup>, Kanita Kayasut<sup>2</sup>, Arnuparp Lekhakula<sup>1</sup>, <sup>1</sup>Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hatyai, Songkhla, Thailand; <sup>2</sup>Division of Pathology, Faculty of Medicine, Prince of Songkla University, Hatyai, Songkhla, Thailand

### **SEQUOIA: RESULTS OF A PHASE 3 RANDOMIZED STUDY OF ZANUBRUTINIB (ZANU) VERSUS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT-NAÏVE (TN) CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL)**

Brad Kahl, MD<sup>1</sup> Krzysztof Giannopoulos, MD<sup>2</sup> Wojciech Jurczak, MD<sup>3</sup> Martin Šimkovic, MD<sup>4</sup> Mazyar Shadman, MD<sup>5</sup> Anders Österborg, MD<sup>6</sup> Luca Laurenti, MD<sup>7</sup> Patricia Walker, MBBS<sup>8</sup> Stephen Opat, MBBS<sup>9</sup> Henry Chan, MBChB<sup>10</sup> Hanna Ciepluch, PhD<sup>11</sup> Richard Greil, MD<sup>12</sup> Monica Tani, MD<sup>13</sup> Marek Trnený, MD<sup>14</sup> Danielle Brander, MD<sup>15</sup> Ian Flinn, MD<sup>16</sup> Sebastian Grosicki, MD<sup>17</sup> Emma Verner, MBBS<sup>18</sup> Jennifer Brown, MD<sup>19</sup> Paolo Ghia, MD<sup>20</sup> Jianyong Li, MD<sup>21</sup> Tian Tian, PhD<sup>22</sup> Lei Zhou, MD<sup>22</sup> Carol Marimpietri, RN<sup>22</sup> Jason Paik, MD<sup>22</sup> Aileen Cohen, MD<sup>22</sup> Jane Huang, MD<sup>22</sup> Tadeusz Robak, MD<sup>23</sup> Peter Hillmen, MBChB<sup>24</sup> Constantine Tam, MD<sup>25</sup>, <sup>1</sup>Washington University School of Medicine, St Louis, MO, USA <sup>2</sup>Medical University of Lublin, Lublin, POL <sup>3</sup>Maria Skłodowska-Curie National Research Institute of Oncology, Krakow, POL <sup>4</sup>University Hospital, Hradec Kralove, CZE <sup>5</sup>Fred Hutchinson Cancer Research Center, Seattle, WA, USA <sup>6</sup>Karolinska Institutet, Stockholm, SWE <sup>7</sup>Fondazione Policlinico Universitario Agostino Gemelli UCSC, Rome, ITA <sup>8</sup>Peninsula Private Hospital, Frankston, VIC, AUS <sup>9</sup>Monash Health, Clayton, VIC, AUS <sup>10</sup>North Shore Hospital, Auckland, NZL <sup>11</sup>Copernicus Regional Oncology Center, Gdansk, POL <sup>12</sup>Paracelsus Medical University, Salzburg, AUT <sup>13</sup>Santa Maria delle Croci Hospital, Ravenna, ITA <sup>14</sup>Charles University General Hospital, Prague, CZE <sup>15</sup>Duke University School of Medicine, Durham, NC, USA <sup>16</sup>Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA <sup>17</sup>Medical University of Silesia, Katowice, POL <sup>18</sup>Concord Repatriation General Hospital, Concord, NSW, AUS <sup>19</sup>Dana-Farber Cancer Institute, Boston, MA, USA <sup>20</sup>Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano, ITA <sup>21</sup>Jiangsu People's Hospital, Nanjing, CHN <sup>22</sup>BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA, USA <sup>23</sup>Medical University of Lodz, Lodz, POL <sup>24</sup>St James's University Hospital, Leeds, GBR <sup>25</sup>Peter MacCallum Cancer Centre, Melbourne, VIC, AUS

### **COST EFFECTIVENESS OF POLATUZUMAB VEDOTIN IN COMBINATION WITH CHEMOIMMUNOTHERAPY IN PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA**

Swetha Kambhampati<sup>1</sup>, Monica Saumoy<sup>2</sup>, Yecheskel Schneider<sup>3</sup>, Stacy Pak<sup>1</sup>, Lihua Elizabeth Budde<sup>1</sup>, Alexey V. Danilov<sup>1</sup>, Matthew G. Mei<sup>1</sup>, Leslie L. Popplewell<sup>1</sup>, Yi-Ping Wen<sup>1</sup>, Jasmine Zain<sup>1</sup>, Stephen J. Forman<sup>1</sup>, Larry W. Kwak<sup>1</sup>, Steven T. Rosen<sup>1</sup>, Alex F. Herrera<sup>1</sup>, Nikhil R. Thiruvengadam<sup>4</sup>, <sup>1</sup>Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA, <sup>2</sup>Center for Digestive Health, Penn Medicine Princeton Medical Center, Plainsboro, NJ, <sup>3</sup>St Luke's University Health Network, Bethlehem, PA, USA, <sup>4</sup>Division of Gastroenterology and Hepatology, Loma Linda University Health, Loma Linda, CA, USA

### **PHASE 2 STUDY OF THE SYK INHIBITOR MIVAVOTINIB IN RELAPSED/REFRACTORY (R/R) NON-GCB DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) WITH OR WITHOUT MYD88 AND/OR CD79 MUTATIONS**

Reem Karmali<sup>1</sup>, Daniel J. Landsburg<sup>2</sup>, Jason Westin<sup>3</sup>, John Leonard<sup>4</sup>, Emil Kuriakose<sup>5</sup>, Bradley Sumrow<sup>5</sup>, Susheela Carroll<sup>5</sup>, Katherine Albert<sup>5</sup>, Natalie Kittrell<sup>5</sup>, Lalith Akella<sup>5</sup>, Leo I. Gordon<sup>1</sup>, <sup>1</sup>Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL; <sup>2</sup>Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; <sup>3</sup>The University of Texas MD Anderson Cancer Center, Houston, TX; <sup>4</sup>Weill Cornell Medical College, New York, NY; <sup>5</sup>Calithera Biosciences, Inc. South San Francisco, CA

### **A SPLICING VARIANT OF AIMP2 INDUCES GERMINAL CENTER ORIGIN B CELL LYMPHOMAGENESIS**

Doyeun Kim<sup>1†</sup>, Seulki Song<sup>2†</sup>, Dongchan Kim<sup>2</sup>, Daeyoon Kim<sup>2</sup>, Dae Gyu Kim<sup>1</sup>, Seohyun Lee<sup>1</sup>, Ji Hun Suh<sup>1</sup>, Sunjae Lee<sup>3</sup>, Yoon Jeon<sup>4</sup>, Ho Lee<sup>5</sup>, Seung Geun Song<sup>7</sup>, Sung-Soo Yoon<sup>6</sup>, Yoon Kyung Jeon<sup>7</sup>, Wonseog Kim<sup>8</sup>, Sunghoon Kim<sup>1,5\*</sup> and Youngil Koh<sup>1,2,6,9\*</sup>, <sup>1</sup> Medicinal Bioconvergence Research Center, Yonsei University, Incheon, Korea <sup>2</sup> Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea <sup>3</sup> Centre for Host-Microbiome Interactions, Faculty of Dentistry, Oral & Craniofacial Sciences, King's College London, UK <sup>4</sup> Division of Convergence Technology, Research Institute National Cancer Center, Goyang, Korea <sup>5</sup> College of Pharmacy and School of Medicine, Yonsei University, Incheon, Korea <sup>6</sup> Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea <sup>7</sup> Department of Pathology, Seoul National University Hospital, Seoul, Korea <sup>8</sup> Department of Internal Medicine, Samsung Medical Center, Seoul, Korea <sup>9</sup> Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea

### **AN UPDATED OVERVIEW OF CLINICAL TRIALS INVESTIGATING IN-CLASS TRANSITION FROM PARENTERAL TO ORAL PROTEASOME INHIBITOR (PI)-BASED TREATMENT WITH IXAZOMIB IN PATIENTS (PTS) WITH MULTIPLE MYELOMA (MM)**

Hans C. Lee<sup>1</sup> Ajay K. Nooka<sup>2</sup> Kenshi Suzuki<sup>3</sup> Presley Whidden<sup>4</sup> Wenming Chen<sup>5</sup> Ruth Williams<sup>4</sup> Renda H. Ferrari<sup>4</sup> Robert M. Rifkin<sup>5</sup> Stephen J. Noga<sup>4</sup>, <sup>1</sup>MD Anderson Cancer Center, Houston, TX, USA; <sup>2</sup>Emory University Hospital/Winship Cancer Institute, Atlanta, GA, USA; <sup>3</sup>Japan Red Cross Medical Center, Shibuya-ku, Tokyo, Japan; <sup>4</sup>Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA, USA; <sup>5</sup>Beijing Chaoyang Hospital, Capital Medical University, Beijing, China; <sup>6</sup>Rocky Mountain Cancer Centers/US Oncology Research, Denver, CO, USA

# E-POSTERS

## **BRUIN CLL-322: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIROBRUTINIB PLUS VENETOCLAX AND RITUXIMAB VERSUS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/ SMALL LYMPHOCYTIC LYMPHOMA (TRIAL IN PROGRESS)**

C. Leow<sup>1</sup>, A. Mato<sup>2</sup>, W. Wierda<sup>3</sup>, J. Pagel<sup>4</sup>, M. Davids<sup>5</sup>, P. Zinzani<sup>6</sup>, Y. Lu<sup>7</sup>, H. Liu<sup>1</sup>, S. Shahda<sup>1</sup>, C. Tam<sup>8</sup>, J. Woyach<sup>9</sup>, T. Eyre<sup>10</sup>, <sup>1</sup>Loxo Oncology at Lilly, Stamford, CT, USA; <sup>2</sup>Memorial Sloan Kettering Cancer Center, New York, USA; <sup>3</sup>MD Anderson Cancer Center, Houston, TX, USA; <sup>4</sup>Swedish Cancer Institute, Seattle, WA, USA; <sup>5</sup>Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA; <sup>6</sup>Institute of Hematology "Seràgnoli" University of Bologna, Bologna Italy; <sup>7</sup>Eli Lilly and Company, Indianapolis, IN, USA; <sup>8</sup>Peter MacCallum Cancer Center, Royal Melbourne Hospital, and University of Melbourne, Melbourne, Australia; <sup>9</sup>The Ohio State University Comprehensive Cancer Center, Columbus, USA; <sup>10</sup>Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, Oxford, UK

## **PIROBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY**

K. Lewis<sup>1</sup>, M. Wang<sup>2</sup>, N. Shah<sup>3</sup>, A. Alencar<sup>4</sup>, J. Gerson<sup>5</sup>, M. Patel<sup>6</sup>, B. Fakhri<sup>7</sup>, W. Jurczak<sup>8</sup>, X. Tan<sup>1</sup>, T. Fenske<sup>3</sup>, C. Coombs<sup>9</sup>, I. Flinn<sup>10</sup>, D. Lewis<sup>11</sup>, S. Le Gouill<sup>12</sup>, M. Palomba<sup>13</sup>, J. Woyach<sup>14</sup>, J. Pagel<sup>15</sup>, N. Lamanna<sup>16</sup>, J. Cohen<sup>17</sup>, M. Barve<sup>18</sup>, P. Ghia<sup>19</sup>, T. Eyre<sup>20</sup>, P. Zinzani<sup>21</sup>, C. Ujjani<sup>22</sup>, Y. Koh<sup>23</sup>, K. Izutsu<sup>24</sup>, E. Lech-Maranda<sup>25</sup>, C. Tam<sup>26</sup>, S. Sundaram<sup>27</sup>, M. Yin<sup>28</sup>, B. Nair<sup>28</sup>, D. Tsai<sup>28</sup>, M. Balbas<sup>28</sup>, A. Mato<sup>13</sup>, C. Cheah<sup>1</sup>, <sup>1</sup>Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia; <sup>2</sup>University of Texas MD Anderson Cancer Center, Houston, USA; <sup>3</sup>Medical College of Wisconsin, Milwaukee, USA; <sup>4</sup>Sylvester Comprehensive Cancer Center, Miami, USA; <sup>5</sup>University of Pennsylvania, Philadelphia, USA; <sup>6</sup>Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, USA; <sup>7</sup>University of California San Francisco, San Francisco, USA; <sup>8</sup>Maria Skłodowska-Curie National Research Institute of Oncology, Krakow, Poland; <sup>9</sup>University of North Carolina at Chapel Hill, Chapel Hill, USA; <sup>10</sup>Sarah Cannon Research Institute, Nashville, USA; <sup>11</sup>University Hospitals Plymouth NHS Trust, Plymouth UK; <sup>12</sup>Service d'hématologie clinique du CHU de Nantes, INSERM CRCINA Nantes-Angers, NeXT Université de Nantes, Nantes, France; <sup>13</sup>Memorial Sloan Kettering Cancer Center, New York, NY, USA; <sup>14</sup>The Ohio State University Comprehensive Cancer Center, Columbus, USA; <sup>15</sup>Swedish Cancer Institute, Seattle, USA; <sup>16</sup>Herbert Irving Comprehensive Cancer Center, Columbia University, New York, USA; <sup>17</sup>Winship Cancer Institute, Emory University, Atlanta, GA, USA; <sup>18</sup>Mary Crowley Cancer Research, Dallas, USA; <sup>19</sup>Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy; <sup>20</sup>Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, Oxford, UK; <sup>21</sup>Institute of Hematology "Seràgnoli" University of Bologna, Bologna Italy; <sup>22</sup>Fred Hutchinson Cancer Research Center, Seattle, USA; <sup>23</sup>Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea; <sup>24</sup>National Cancer Center Hospital, Tokyo, Japan; <sup>25</sup>Institute of Hematology and Transfusion Medicine, Warsaw, Poland; <sup>26</sup>Peter MacCallum Cancer Center, Royal Melbourne Hospital, and University of Melbourne, Melbourne, Australia; <sup>27</sup>Department of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY; <sup>28</sup>Loxo Oncology at Lilly, Stamford, CT, USA

## **ENCORE: THE IMPACT OF CLASSIC HODGKIN LYMPHOMA (CHL) ON INFORMAL CAREGIVERS: RESULTS FROM THE CHL: REAL-WORLD OBSERVATIONS FROM PHYSICIANS, PATIENTS, AND CAREGIVERS ON THE DISEASE AND ITS TREATMENT (CONNECT) STUDY**

Darcy R. Flora<sup>1</sup>; Andrew M. Evens<sup>2</sup>; Nicholas Liu<sup>3</sup>; Kristina S. Yu<sup>3</sup>; Rachel Byrd<sup>1</sup>; Supriya Kumar<sup>4</sup>; Michelle Fanale<sup>3</sup>; Katie Holmes<sup>4</sup>; Carlos Flores<sup>5</sup>; Andy Surinach<sup>5</sup>; Susan K. Parsons<sup>6</sup> (\*at time of study); <sup>1</sup>GRYT Health, Rochester, NY, USA; <sup>2</sup>Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA; <sup>3</sup>Seagen Inc., Bothell, WA, USA; <sup>4</sup>Ipsos Healthcare, New York, NY, USA; <sup>5</sup>Genesis Research, Hoboken, NJ, USA; <sup>6</sup>Tufts Medical Center, Boston, MA, USA

## **THE VALUE TO SOCIETY OF ADVANCING THE CARE OF PATIENTS WITH FIXED TREATMENT DURATION IN CHRONIC LYMPHOCYTIC LEUKEMIA**

P Pednekar<sup>(a)</sup>, BS Manzoor<sup>(b)</sup>, S Chung<sup>(a)</sup>, AP Skarbnik<sup>(c)</sup>, D Jawaid<sup>(b)</sup>, K Sail<sup>(b)</sup>, P Sullivan<sup>(a)</sup>, PRECISIONheor, New York, NY, USA; <sup>(b)</sup>AbbVie, North Chicago, Illinois, USA; <sup>(c)</sup>Novant Health Cancer Institute, Charlotte, NC, USA

## **COST-EFFECTIVENESS OF POLATUZUMAB VEDOTIN IN PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA**

Matthew Matasar<sup>1</sup>, Anthony Mazaquel<sup>2</sup>, Rodrigo Ho<sup>3</sup>, Aino Launonen<sup>3</sup>, Carmen Ng<sup>2</sup>, Rongrong Wang<sup>2</sup>, David Fox<sup>2</sup>, Farah Hossain<sup>2</sup>, Jia Li<sup>2</sup>, Joshua A. Roth<sup>2</sup>, John M. Burke<sup>4</sup>, <sup>1</sup>Memorial Sloan Kettering Cancer Center, New York, NY, USA; <sup>2</sup>Genentech, Inc., South San Francisco, CA, USA; <sup>3</sup>F. Hoffmann-La Roche Ltd., Basel, Switzerland; <sup>4</sup>Rocky Mountain Cancer Centers/US Oncology, Aurora, CO, USA

## **MAJIC: A PHASE 3 PROSPECTIVE, MULTICENTER, RANDOMIZED, OPEN-LABEL TRIAL OF ACALABRUTINIB PLUS VENETOCLAX VERSUS VENETOCLAX PLUS OBINUTUZUMAB IN PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA**

Anthony Mato<sup>1</sup>, Jeff P. Sharman<sup>2</sup>, Juliette Hum<sup>3</sup>, Susana Wargo<sup>4</sup>, Ugochinyere Emeribe<sup>4</sup>, Mina Shahkarami<sup>5</sup>, Hasan K. Alhasani<sup>6</sup>, Juliana Biondo<sup>7</sup>, Sarang Abhyankar<sup>7</sup>, Rick Hermann<sup>4</sup>, Matthew S. Davids<sup>8</sup>, <sup>1</sup>Memorial Sloan Kettering Cancer Center, New York, NY; <sup>2</sup>Willamette Valley Cancer Institute, Institute/US Oncology Research, Eugene, OR; <sup>3</sup>AstraZeneca, Mississauga, Ontario, Canada; <sup>4</sup>AstraZeneca, Gaithersburg, MD; <sup>5</sup>AstraZeneca, South San Francisco, CA; <sup>6</sup>AbbVie Inc., North Chicago, IL; <sup>7</sup>Genentech, South San Francisco, CA; <sup>8</sup>Dana Farber Cancer Institute, Boston, MA

## **THROMBOTIC MICROANGIOPATHY AFTER COVID-19 VACCINATION IN THE POST-TRANSPLANT PATIENT: A CASE PRESENTATION**

Adrienne Maurer, ARNP; Bart Scott, MD, Fred Hutchinson Cancer Center/ University of Washington – Seattle, WA, USA



### **PATIENT-CENTRIC OUTCOMES AMONG PATIENTS WITH FOLLICULAR LYMPHOMA TREATED IN THE REAL-WORLD SETTING**

Ali McBride,<sup>1</sup> Cherrishe Brown-Bickerstaff,<sup>2</sup> Scott Keating,<sup>1</sup> Andrew J. Klink,<sup>2</sup> Ashley Saunders,<sup>1</sup> Djibril Liassou,<sup>2</sup> Ajeet Gajra,<sup>2</sup> Bristol Myers Squibb, Princeton, NJ, USA; <sup>2</sup>Cardinal Health Specialty Solutions, Dublin, OH, USA

### **POLATUZUMAB VEDOTIN PLUS RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE (POLA-R-CHP) VERSUS RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE AND PREDNISONE (R-CHOP) THERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): RESULTS FROM THE PHASE III POLARIX STUDY**

N. Mehta-Shah,<sup>1</sup> H. Tilly,<sup>2</sup> F. Morschhauser,<sup>3</sup> L.H. Sehn,<sup>4</sup> J.W. Friedberg,<sup>5</sup> M. Trnený,<sup>6</sup> J.P. Sharman,<sup>7</sup> C. Herbaux,<sup>8</sup> J.M. Burke,<sup>9</sup> M. Matasar,<sup>10</sup> S. Rai,<sup>11</sup> K. Izutsu,<sup>12</sup> L. Oberic,<sup>13</sup> A. Chauchet,<sup>14</sup> W. Jurczak,<sup>15</sup> Y. Song,<sup>16</sup> R. Greil,<sup>17</sup> L. Mykhalska,<sup>18</sup> J.M.B. Burgués,<sup>19</sup> M.C. Cheung,<sup>20</sup> A. Pinto,<sup>21</sup> H-J. Shin,<sup>22</sup> G. Hapgood,<sup>23</sup> E. Munhoz,<sup>24</sup> P. Abrisqueta,<sup>25</sup> J-P. Gau,<sup>26</sup> J. Hirata,<sup>27</sup> Y. Jiang,<sup>27</sup> M. Yan,<sup>28</sup> C. Lee,<sup>27</sup> C. Flowers,<sup>29</sup> G. Salles<sup>30</sup>, <sup>1</sup>Washington University in St. Louis, St. Louis, MO, USA; <sup>2</sup>Centre Henri Becquerel and University of Rouen, Rouen, France; <sup>3</sup>Univ. Lille, CHU Lille, ULR 7365 – GRITA – Group de Recherche sur les formes Injectables et les Technologies Associées, Lille, France; <sup>4</sup>BC Cancer Centre for Lymphoid Cancer and the University of British Columbia, Vancouver, Canada; <sup>5</sup>Wilmot Cancer Institute, University of Rochester, Rochester, NY, USA; <sup>6</sup>First Faculty of Medicine, Charles University, General Hospital, Prague, Czech Republic; <sup>7</sup>Willamette Valley Cancer Institute/US Oncology, Eugene, OR, USA; <sup>8</sup>CHU de Montpellier, Montpellier, France; <sup>9</sup>Rocky Mountain Cancer Centers/US Oncology, Aurora, CO, USA; <sup>10</sup>Memorial Sloan Kettering Cancer Center, New York City/Montvale, NY/NJ, USA; <sup>11</sup>Kindai University, Faculty of Medicine, Osaka-Sayama City, Japan; <sup>12</sup>National Cancer Center Hospital, Tokyo, Japan; <sup>13</sup>Institut Universitaire du Cancer, Toulouse-Oncopole, Toulouse, France; <sup>14</sup>CHRU Besançon, Besançon, France; <sup>15</sup>Maria Skłodowska – Curie National Research Institute of Oncology, Kraków, Poland; <sup>16</sup>Peking University Cancer Hospital, Beijing, China; <sup>17</sup>Paracelsus Medical University, Salzburg Cancer Research Institute-CCCIT and Cancer Cluster Salzburg, Salzburg, Austria; <sup>18</sup>Clinical Hospital Feofaniya, Kyiv, Ukraine; <sup>19</sup>Hospital San Pedro de Alcántara, Cáceres, Spain; <sup>20</sup>Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada; <sup>21</sup>Hematology-Oncology & Stem Cell Transplantation Unit, Istituto Nazionale Tumori, Fondazione ‘G. Pascale’, IRCCS, Naples, Italy; <sup>22</sup>Medical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea; <sup>23</sup>Princess Alexandra Hospital, Brisbane, Australia; <sup>24</sup>Hospital Erasto Gaertner, Curitiba, Brazil; <sup>25</sup>Hospital Vall d’Hebron, Vall d’Hebron Institute of Oncology, Barcelona, Spain; <sup>26</sup>Taipei Veterans General Hospital, Taipei, Taiwan; <sup>27</sup>Genentech, Inc., South San Francisco, CA, USA; <sup>28</sup>F. Hoffmann-La Roche Ltd, Mississauga, Canada; <sup>29</sup>MD Anderson Cancer Center, Houston, TX, USA; <sup>30</sup>Memorial Sloan Kettering Cancer Center, New York City, NY, USA

### **CASE STUDY: PHOTOSENSITIVITY RASH ASSOCIATED WITH LONCASTUXIMAB TESERINE**

Mistry, H. E. and Ahmed, S., The University of Texas MD Anderson Cancer Center, Houston, TX, USA

### **ROLE OF ADVANCED PRACTICE PROVIDERS (APP’S) IN IDENTIFYING POST CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH) OR MACROPHAGE ACTIVATION SYNDROME (MAS)**

Murphy, K. C., Mistry, H. E., and Ahmed, S., The University of Texas MD Anderson Cancer Center, Houston, Texas, USA | Department of Lymphoma/Myeloma

### **CB-010, A CRISPR-EDITED ALLOGENEIC ANTI-CD19 CAR -T CELL THERAPY WITH A PD-1 KNOCK OUT, IN PATIENTS WITH RELAPSED OR REFRACTORY B CELL NON-HODGKIN LYMPHOMA (ANTLER STUDY)**

Loretta J. Nastoupil<sup>1</sup>, Susan O’Brien<sup>2</sup>, Houston E. Holmes<sup>3</sup>, Ly Dsouza<sup>1</sup>, Doug Hart<sup>4</sup>, Emiri Matsuda<sup>5</sup>, Tarah SatterfieldLedbetter<sup>6</sup>, Justin Skoble<sup>7</sup>, Elizabeth Garner<sup>7</sup>, Mara Bryan<sup>7</sup>, Steven Kanner<sup>7</sup>, Ella Li<sup>8</sup>, Syed Rizvi<sup>7</sup>, and James Essell<sup>9</sup>, <sup>1</sup>Lymphoma/Myeloma, UT MD Anderson Cancer Center, Houston, <sup>2</sup>Department of Hematology and Oncology, University of California Irvine, Irvine, <sup>3</sup>Oncology, Texas Oncology/Baylor Sammons Cancer Center, Dallas, <sup>4</sup>Research, Oncology Hematology Care, Cincinnati, <sup>5</sup>UCI Cancer Center, University of California Irvine, Irvine, <sup>6</sup>Clinical Oncology Research Coordination, Baylor Research Institution, Dallas, <sup>7</sup>Caribou Biosciences, Inc., Berkeley, <sup>8</sup>EffectStats LLC, Cambridge, <sup>9</sup>Blood Cancer, Oncology Hematology Care, Cincinnati, USA

### **SUBGROUP ANALYSIS IN RE-MIND2, AN OBSERVATIONAL, RETROSPECTIVE COHORT STUDY OF TAFASITAMAB + LENALIDOMIDE VERSUS SYSTEMIC THERAPIES IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA**

Grzegorz S. Nowakowski,<sup>1</sup> Dok Hyun Yoon,<sup>2</sup> Erel Joffe,<sup>3</sup> Pier Luigi Zinzani,<sup>4,5</sup> Lorenzo Sabatelli,<sup>6</sup> Eva E. Waltl,<sup>7</sup> Carmelita G. Alvero,<sup>8</sup> Georg Hess,<sup>9</sup> Peter A. Riedell,<sup>10</sup> Kibum Kim,<sup>11,12</sup> Diana Brixner,<sup>11</sup> Gilles Salles<sup>3</sup>, <sup>1</sup>Division of Hematology, Mayo Clinic, Rochester, MN, USA; <sup>2</sup>Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; <sup>3</sup>Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; <sup>4</sup>IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia “Seràgnoli”, Bologna, Italy; <sup>5</sup>Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università di Bologna, Bologna, Italy; <sup>6</sup>Incyte Biosciences International Sàrl, Morges, Switzerland; <sup>7</sup>MorphoSys AG, Planegg, Germany; <sup>8</sup>MorphoSys US Inc, Boston, MA, USA; <sup>9</sup>Department of Hematology, Oncology and Pneumology, University Medical Center, Johannes Gutenberg-University, Mainz, Germany; <sup>10</sup>Division of Hematology and Oncology, University of Chicago Medicine, Chicago, IL, USA; <sup>11</sup>Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT, USA; <sup>12</sup>Department of Pharmacy, Systems, Outcomes and Policy, University of Illinois at Chicago, Chicago, IL, USA

# E-POSTERS

## **ENCORE: CLASSIC HODGKIN LYMPHOMA: REAL-WORLD OBSERVATIONS FROM PHYSICIANS, PATIENTS, AND CAREGIVERS ON THE DISEASE AND ITS TREATMENT (CONNECT): OBSERVATIONS OF PHYSICIANS ON TREATMENT AND INTERIM PET-ADAPTED REGIMENS**

[Susan K. Parsons](#)<sup>1</sup>; Kristina S. Yu<sup>2</sup>; Nicholas Liu<sup>2</sup>; Supriya Kumar<sup>3\*</sup>; Michelle Fanale<sup>2</sup>; Katie Holmes<sup>3</sup>; Carlos Flores<sup>4</sup>; Andy Surinach<sup>4</sup>; Darcy R. Flora<sup>5</sup>; Andrew M. Evens<sup>6</sup>, (\* at time of study): <sup>1</sup>Tufts Medical Center, Boston, MA, USA; <sup>2</sup>Seagen Inc., Bothell, WA, USA; <sup>3</sup>Ipsos Healthcare, New York, NY, USA; <sup>4</sup>Genesis Research, Hoboken, NJ, USA; <sup>5</sup>GRYT Health, Rochester, NY, USA; <sup>6</sup>Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA

## **AN ONCOLOGY SIMULATION MODEL TO ESTIMATE 10-YEAR OVERALL SURVIVAL, PROGRESSION-FREE SURVIVAL, AND STEM CELL TRANSPLANTATION FOR FRONTLINE, STAGE III OR IV CLASSICAL HODGKIN LYMPHOMA BASED ON THE OVERALL SURVIVAL UPDATE OF THE ECHELON-1 TRIAL: A UNITED STATES PERSPECTIVE**

[Tycel Phillips](#)<sup>1</sup>, Kristen Migliaccio-Walle<sup>2</sup>, Kristina S. Yu<sup>3</sup>, Brian Bloudek<sup>2</sup>, Nicholas Liu<sup>3</sup>, John M. Burke<sup>4</sup>, <sup>1</sup>Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Medical School, Ann Arbor, MI; <sup>2</sup>Curta, Inc., Seattle, WA; <sup>3</sup>Seagen Inc., Bothell, WA; <sup>4</sup>US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, Aurora, CO

## **AUTOLOGOUS STEM CELL TRANSPLANTATION OUTCOMES IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: A MULTICENTER, RETROSPECTIVE ANALYSIS**

[Nicholas Schmidt](#)<sup>1</sup>, Y. Samara<sup>2</sup>, M. Mei<sup>2</sup>, S. Huntington<sup>3</sup>, M. Di<sup>3</sup>, J. Day<sup>4</sup>, B. Link<sup>4</sup>, Y. Sawalha<sup>5</sup>, R. Karmali<sup>6</sup>, S. Bair<sup>7</sup>, M. Kamdar<sup>7</sup>, Z. Win Myint<sup>8</sup>, N. Grover<sup>9</sup>, and E. Ayers<sup>1</sup>, <sup>1</sup>University of Virginia, Charlottesville, VA <sup>2</sup>City of Hope National Medical Center, Duarte, CA <sup>3</sup>Yale University, New Haven, CT <sup>4</sup>University of Iowa, Iowa City, IA <sup>5</sup>Ohio State University, Columbus OH <sup>6</sup>Northwestern University, Chicago, IL <sup>7</sup>University of Colorado, Aurora, CO <sup>8</sup>University of Southern California, Los Angeles, CA <sup>9</sup>University of North Carolina, Chapel Hill, NC

## **FIRST-LINE BRENTUXIMAB VEDOTIN PLUS CHEMOTHERAPY IMPROVES OVERALL SURVIVAL IN PATIENTS WITH STAGE III/IV CLASSICAL HODGKIN LYMPHOMA: AN UPDATED ANALYSIS OF ECHELON-1**

[Radhakrishnan Ramchandren](#)<sup>1</sup>, Stephen M. Ansell<sup>2</sup>, Joseph M. Connors<sup>3</sup>, John A. Radford<sup>4</sup>, Won Seog Kim<sup>5</sup>, Andrea Gallamini<sup>5</sup>, Jonathan W. Friedberg<sup>7</sup>, Ranjana H. Advani<sup>8</sup>, Martin Hutchings<sup>9</sup>, Andrew M. Evens<sup>10</sup>, Piotr Smolewski<sup>11</sup>, Kerry J. Savage<sup>3</sup>, Nancy L. Bartlett<sup>12</sup>, Hyeon Seok Eom<sup>13</sup>, Jeremy S. Abramson<sup>14</sup>, Cassie Dong<sup>15</sup>, Frank Campana<sup>15</sup>, Keenan Fenton<sup>16</sup>, Markus Puhlmann<sup>16</sup>, David J. Straus<sup>17</sup>, <sup>1</sup>The University of Tennessee Graduate School of Medicine, Knoxville, TN, USA; <sup>2</sup>Mayo Clinic, Rochester, MN, USA; <sup>3</sup>BC Cancer Centre for Lymphoid Cancer and Department of Medical Oncology, Vancouver, BC, Canada; <sup>4</sup>University of Manchester, Christie Hospital NHS Foundation Trust,

Manchester, United Kingdom; <sup>5</sup>Division of Hematology-Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South); <sup>6</sup>Research Innovation and Statistics, Antoine-Lacassagne Cancer Centre, Nice, France; <sup>7</sup>James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA; <sup>8</sup>Department of Medicine, Division of Oncology, Stanford University, Stanford, CA, USA; <sup>9</sup>Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; <sup>10</sup>Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA; <sup>11</sup>Department of Experimental Hematology, Medical University of Lodz, Lodz, Poland; <sup>12</sup>Washington University School of Medicine Siteman Cancer Center, St. Louis, MO, USA; <sup>13</sup>Center for Hematologic Malignancy, National Cancer Center, Goyang, Korea, Republic of (South); <sup>14</sup>Massachusetts General Hospital, Boston, MA, USA; <sup>15</sup>Takeda Development Center Americas, Inc. (TOCA), Lexington, MA, USA; <sup>16</sup>Seagen Inc., Bothell, WA, USA; <sup>17</sup>Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA

## **SUBCUTANEOUS EPCORITAMAB + R-DHAX/C IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT (ASCT): PRELIMINARY PHASE 1/2 RESULTS**

Pau Abrisqueta, MD, PhD,<sup>1</sup> Lorenzo Falchi, MD,<sup>2</sup> Tycel Phillips, MD,<sup>3</sup> Sven de Vos, MD, PhD,<sup>4</sup> Marcel Nijland, MD, PhD,<sup>5</sup> Fritz Offner, MD, PhD,<sup>6</sup> Irina Bykhovski, PharmD,<sup>7</sup> Jun Wu, MD, MS,<sup>8</sup> Liwei Wang, PhD,<sup>7</sup> [Ali Rana, MD, PhD](#),<sup>7</sup> Raul Cordoba, MD, PhD<sup>9</sup> <sup>1</sup>Hospital Universitario Vall d'Hebron, Barcelona, Spain; <sup>2</sup>Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA; <sup>3</sup>University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA; <sup>4</sup>Ronald Reagan University of California Los Angeles Medical Center, Los Angeles, CA, USA; <sup>5</sup>University Medical Center Groningen and University of Groningen, Groningen, Netherlands; <sup>6</sup>Universitair Ziekenhuis Gent, Ghent, Belgium; <sup>7</sup>Genmab, Princeton, NJ, USA; <sup>8</sup>AbbVie, North Chicago, IL, USA; <sup>9</sup>Fundacion Jimenez Diaz University Hospital, Health Research Institute IIS-FJD, Madrid, Spain

## **HEMOPHAGOCYtic LYMPHOHISTIOCYTOSIS (HLH) AND EBSTEIN-BARR VIRUS (EBV) POSITIVE CLASSIC HODGKIN'S LYMPHOMA (CHL) FOLLOWING SARS-COV-2 INFECTION**

[SK Reddy](#), AG Antun, W Harris, B El Osta, M Shumate, R Gnanajothy, MA Ribeiro, Atlanta VA Medical Center, Decatur, GA, USA

## **UPPER GASTROINTESTINAL (GI) DISEASE MORBIDITY, PEPTIC ULCER EVENT RISK, AND GASTRIC ACID-REDUCING AGENT (GARA) USE IN PATIENTS (PTS) WITH MANTLE CELL LYMPHOMA (MCL) OR CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LEUKEMIA (CLL/SLL)**

[Olga Ryan](#),<sup>1</sup> Swetha Challagulla,<sup>2</sup> Kojo Osei-Bonsu,<sup>2</sup> Daniel Mercer,<sup>3</sup> Haiyan Sun,<sup>3</sup> Naijun Chen,<sup>1</sup> Jacqueline Nielsen,<sup>1</sup> Samuel Crawford,<sup>1,4</sup> [Raisa Volodarsky](#),<sup>2</sup> <sup>1</sup>AbbVie, Inc., Chicago, IL, USA; <sup>2</sup>Pharmacyclics LLC, South San Francisco, CA, USA; <sup>3</sup>Genesis Research, Hoboken, NJ, USA; <sup>4</sup>University of Southern California, Los Angeles, CA, USA

### **CD30+ ALK+ PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA MASQUERADING AS CELLULITIS**

Christopher Sandifer DO<sup>1,2</sup>, Anna-Lena Meinhardt MD<sup>1,2</sup>, Philip J. Cohen MD<sup>3</sup>, Robert Cole MD<sup>4</sup>, Donghong Cai MD<sup>5</sup>, Victor T. Chang MD<sup>1,6</sup>, <sup>1</sup>Department of Medicine, Rutgers - New Jersey Medical School, Newark, NJ, USA <sup>2</sup>Medicine Service, VA New Jersey Health Care System, East Orange, NJ, USA (VANJHCS) <sup>3</sup>Dermatology, VANJHCS. <sup>4</sup>Radiation Oncology, VANJHCS. <sup>5</sup>Pathology & Laboratory Services, VANJHCS. <sup>6</sup>Hematology-Oncology, VANJHCS.

### **REAL-WORLD ANALYSIS OF BRENTUXIMAB VEDOTIN MONOTHERAPY RE-TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY CHL OR PTCL: A RETROSPECTIVE US CLAIMS ANALYSIS**

Dahlia Sano<sup>1</sup>, Nicholas Liu<sup>2</sup>, Scott Knowles<sup>2</sup>, Joanna P. MacEwan<sup>3</sup>, Shu Wang<sup>3</sup>, Jenifer Wogen<sup>3</sup>, Kristina S. Yu<sup>2</sup>, Seung Tae Lee<sup>4</sup>, Karmanos Cancer Center, Detroit, MI, USA; <sup>2</sup>Seagen Inc., Bothell, WA, USA; <sup>3</sup>Genesis Research, Hoboken, NJ, USA; <sup>4</sup>University of Maryland Medical System, Baltimore, MD, USA

### **ZANUBRUTINIB IN 13 ACALABRUTINIB-INTOLERANT PATIENTS (PTS) WITH B-CELL MALIGNANCIES**

Mazyar Shadman, MD, MPH<sup>1</sup> Ian W. Flinn, MD, PhD<sup>2</sup> Edwin C. Kingsley, MD<sup>3</sup> Benjamin Freeman, MD<sup>4</sup> Moshe Y. Levy, MD<sup>5</sup> Jennifer Cultrera, MD<sup>6</sup> Charles M. Farber, MD<sup>7</sup> Arvind Chaudhry, MD, PhD<sup>8</sup> Ryan Porter, MD<sup>9</sup> Rocco Crescenzo, MD<sup>10</sup> Adam Idoine, PhD<sup>10</sup> Xiaoping Zhang, MD<sup>10</sup> Aileen Cohen, MD, PhD<sup>10</sup> Kunthe By, PhD<sup>10</sup> Jane Huang, MD<sup>10</sup> Jeff P. Sharman, MD<sup>11</sup>, <sup>1</sup>Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA <sup>2</sup>Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA <sup>3</sup>Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA <sup>4</sup>Summit Medical Group, Florham Park, NJ, USA <sup>5</sup>Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX, USA <sup>6</sup>Florida Cancer Specialists & Research Institute, Leesburg, FL, USA <sup>7</sup>Atlantic Hematology Oncology, Morristown Medical Center, Morristown, NJ, USA <sup>8</sup>Summit Cancer Centers, Spokane, WA, USA <sup>9</sup>SSM Health Dean Medical Group, Madison, WI, USA <sup>10</sup>BeiGene (Beijing) Co., Ltd., Beijing, China & BeiGene USA, Inc., San Mateo, CA, USA <sup>11</sup>Willamette Valley Cancer Institute & Research Center, Eugene, OR, USA

### **PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED CLL/SLL: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY**

N. Shah<sup>1</sup>, A. Mato<sup>2</sup>, J. Pagel<sup>3</sup>, C. Coombs<sup>4</sup>, N. Lamanna<sup>5</sup>, T. Munir<sup>6</sup>, E. Lech-Maranda<sup>7</sup>, T. Eyre<sup>8</sup>, J. Woyach<sup>9</sup>, W. Wierda<sup>10</sup>, C. Cheah<sup>11</sup>, J. Cohen<sup>12</sup>, L. Roeker<sup>1</sup>, M. Patel<sup>13</sup>, B. Fakhri<sup>14</sup>, M. Barve<sup>15</sup>, C. Tam<sup>16</sup>, D. Lewis<sup>17</sup>, J. Gerson<sup>18</sup>, A. Alencar<sup>19</sup>, C. Ujjani<sup>20</sup>, I. Flinn<sup>21</sup>, S. Sundaram<sup>22</sup>, S. Ma<sup>23</sup>, D. Jagadeesh<sup>24</sup>, J. Rhodes<sup>25</sup>, J. Taylor<sup>19</sup>, O. Abdel-Wahab<sup>2</sup>, P. Ghia<sup>26</sup>, S. Schuster<sup>18</sup>, D. Wang<sup>27</sup>, B. Nair<sup>27</sup>, E. Zhu<sup>27</sup>, D. Tsai<sup>27</sup>, M. Davids<sup>28</sup>, J. Brown<sup>28</sup>, W. Jurczak<sup>29</sup>, <sup>1</sup>Medical College of Wisconsin, Milwaukee, WI, USA; <sup>2</sup>Memorial Sloan Kettering Cancer Center, New York, NY, USA; <sup>3</sup>Swedish Cancer Institute, Seattle, WA, USA; <sup>4</sup>University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; <sup>5</sup>Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA; <sup>6</sup>Department of Haematology, St. James's University Hospital, Leeds, UK; <sup>7</sup>Institute of Hematology and Transfusion Medicine, Warsaw, Poland; <sup>8</sup>Oxford University Hospitals NHS

Foundation Trust, Churchill Cancer Center, Oxford, UK; <sup>9</sup>The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA; <sup>10</sup>MD Anderson Cancer Center, Houston, TX, USA; <sup>11</sup>Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia; <sup>12</sup>Winship Cancer Institute, Emory University, Atlanta, GA, USA; <sup>13</sup>Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, USA; <sup>14</sup>University of California San Francisco, San Francisco, CA, USA; <sup>15</sup>Mary Crowley Cancer Research, Dallas, TX, USA; <sup>16</sup>Peter MacCallum Cancer Center, Royal Melbourne Hospital, and University of Melbourne, Melbourne, Australia; <sup>17</sup>Plymouth Hospitals NHS Trust - Derriford Hospital, Plymouth, UK; <sup>18</sup>Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA; <sup>19</sup>University of Miami Miller School of Medicine, Miami, FL, USA; <sup>20</sup>Fred Hutchinson Cancer Research Center, Seattle, WA, USA; <sup>21</sup>Sarah Cannon Research Institute, Nashville, TN, USA; <sup>22</sup>Department of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; <sup>23</sup>Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA; <sup>24</sup>Cleveland Clinic, Cleveland, OH, USA; <sup>25</sup>Northwell Health Cancer Institute, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Health, New Hyde Park, NY, USA; <sup>26</sup>Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy; <sup>27</sup>Loxo Oncology at Lilly, Stamford, CT, USA; <sup>28</sup>Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA; <sup>29</sup>Maria Skłodowska-Curie National Research Institute of Oncology, Krakow, Poland

### **TDT+ BLASTOID B-CELL NEOPLASM PRESENTED IN BONE MARROW: IS IT LYMPHOMA OR ACUTE B LYMPHOBLASTIC LEUKEMIA?**

Shaoying Li, Department of Hematopathology, UT MD Anderson Cancer Center, Houston, TX, USA

### **A MULTICOHORT, OPEN-LABEL, PHASE 2 STUDY OF A COFORMULATION OF VIBOSTOLIMAB AND PEMBROLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) HEMATOLOGIC MALIGNANCIES: KEYVIBE-004**

Geoffrey Shouse<sup>1</sup>; Thomas Jemielita<sup>2</sup>; Rushdia Yusuf<sup>2</sup>; Akash Nahar<sup>2</sup>, <sup>1</sup>Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA; <sup>2</sup>Merck & Co., Inc., Kenilworth, NJ, USA

### **INDIRECT COMPARISONS OF EFFICACY OF ZANUBRUTINIB VERSUS ORELABRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA OR RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA**

Yugin Song<sup>1</sup>, Keshu Zhou<sup>2</sup>, Shenmiao Yang<sup>3</sup>, Jianfeng Zhou<sup>4</sup>, Jianda Hu<sup>5</sup>, Dehui Zou<sup>6</sup>, Sujun Gao<sup>7</sup>, Ling Pan<sup>8</sup>, Tingyu Wang<sup>6</sup>, Haiyan Yang<sup>9</sup>, Huilai Zhang<sup>10</sup>, Daobin Zhou<sup>11</sup>, Jie Ji<sup>8</sup>, Wei Xu<sup>12</sup>, Ru Feng<sup>13</sup>, Jie Jin<sup>14</sup>, Fangfang Lv<sup>15</sup>, Haiwen Huang<sup>16</sup>, Xiaosi Fan<sup>17</sup>, Sheng Xu<sup>17</sup>, Jun Zhu<sup>1\*</sup>, <sup>1</sup>Peking University Cancer Hospital & Institute (Beijing Cancer Hospital), Beijing, China, <sup>2</sup>Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China, <sup>3</sup>Peking University Peoples Hospital, Peking University Institute of Hematology, Beijing, China, <sup>4</sup>Tongji Hospital, Tongji Medical College, Wuhan, China, <sup>5</sup>Fujian Medical University Union

# E-POSTERS

Hospital, Fuzhou, China, <sup>6</sup>Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, <sup>7</sup>The First Hospital of Jilin University, Changchun, China, <sup>8</sup>West China Hospital of Sichuan University, Chengdu, China, <sup>9</sup>The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China, <sup>10</sup>Tianjin Medical University Cancer Institute and Hospital, Tianjin, China, <sup>11</sup>Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, <sup>12</sup>The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China, <sup>13</sup>Nanfeng Hospital of Southern Medical University, Guangzhou, China, <sup>14</sup>The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, China, <sup>15</sup>Fudan University Shanghai Cancer Center, Shanghai, China, <sup>16</sup>The First Hospital of Soochow University, Suzhou, China, <sup>17</sup>BeiGene (Beijing) Co., Ltd., Beijing, China

## **TRIAL IN PROGRESS: A PHASE 1B/2 STUDY OF GB5121, A NOVEL, HIGHLY SELECTIVE, POTENT, AND CNS-PENETRANT BTK INHIBITOR FOR RELAPSED/REFRACTORY PRIMARY/SECONDARY CNS LYMPHOMA AND PRIMARY VITREORETINAL LYMPHOMA**

Carole Soussain<sup>1</sup>, Christian Grommes<sup>2</sup>, Samar Issa<sup>3</sup>, Renee Ward<sup>4</sup>, Caryn Peterson<sup>4</sup>, Matt Cravets<sup>4</sup>, Anita Mathias<sup>4</sup>, Judith Sosa<sup>4</sup>, Brian Kirby<sup>4</sup>, Zhaoqing Ding<sup>4</sup>, Isharat Yusuf<sup>4</sup>, Mark Rose<sup>4</sup>, Marcos Steinberg<sup>4</sup>, Han W. Tun<sup>5</sup>, <sup>1</sup>Institut Curie, Saint-Cloud, France; <sup>2</sup>Memorial Sloan Kettering Cancer Center, New York, NY, USA; <sup>3</sup>Middlemore Hospital, Auckland, New Zealand; <sup>4</sup>Gossamer Bio, Inc., San Diego, CA, USA; <sup>5</sup>Mayo Clinic, Jacksonville, FL, USA

## **FACTORS ASSOCIATED WITH 100-DAY MORTALITY AFTER CD19 CAR-T THERAPY**

Kevin Tang<sup>1</sup>, Raamis Khawaja<sup>2</sup>, Lei Feng<sup>3</sup>, Paolo Strati<sup>6</sup>, Raphael Steiner<sup>6</sup>, Ranjit Nair<sup>6</sup>, Christopher Flowers<sup>6</sup>, Neeraj Saini<sup>5</sup>, Jeremy Ramdial<sup>5</sup>, Samer Srour<sup>5</sup>, Richard Champlin<sup>5</sup>, Gabriela Rondon<sup>5</sup>, Janet Torres<sup>5</sup>, Partow Kebriaei<sup>5</sup>, Loretta Nastoupil<sup>6</sup>, Maria A. Rodriguez<sup>6</sup>, Haleigh Mistry<sup>6</sup>, Elizabeth J Shpall<sup>5</sup>, Yago Nieto<sup>5</sup>, Jason Westin<sup>6</sup>, Sattva Neelapu<sup>6</sup>, Sairah Ahmed<sup>6,5</sup>, <sup>1</sup>Dept of Medicine, Baylor College of Medicine, Houston, TX USA <sup>2</sup>Dept of Medicine, MD Anderson Cancer Center Houston, TX, USA <sup>3</sup>Dept of Medicine, University of Texas, Houston, Texas, USA <sup>4</sup>Dept of Biostatistics, MD Anderson Cancer Center, Houston Texas, USA <sup>5</sup>Dept of Stem Cell Transplant, MD Anderson Cancer Center, Houston, Texas, USA <sup>6</sup>Dept of Lymphoma/Myeloma, MD Anderson Cancer Center, Houston, Texas, USA

## **OPEN-LABEL PHASE 2 STUDY OF THE EFFICACY AND SAFETY OF PEMBROLIZUMAB ADMINISTERED EVERY 6 WEEKS IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA OR PRIMARY MEDIASTINAL B-CELL LYMPHOMA: KEYNOTE B68**

Philippe Armand<sup>1</sup>; Kumudu Pathiraja<sup>2</sup>; Samhita Chakraborty<sup>2</sup>; Akash Nahar<sup>2</sup>; Sarah Tomassetti<sup>3</sup>, <sup>1</sup>Dana-Farber Cancer Institute, Boston, MA, USA; <sup>2</sup>Merck & Co., Inc., Kenilworth, NJ, USA; <sup>3</sup>Harbor-UCLA Medical Center, Torrance, CA, USA

## **MULTIVALENT RITUXIMAB ZEIN NANOPARTICLES FOR IMPROVED LYMPHOMA THERAPIES: A PRECLINICAL INVESTIGATION**

Courtney van Ballegooye<sup>1,2</sup>, Dr. Donald Yapp<sup>3</sup>, and Dr. Marcel Bally<sup>2,4</sup>, <sup>1</sup>University of British Columbia Faculty of Medicine, Vancouver, B.C., Canada; <sup>2</sup>British Columbia Cancer Research Institute, Vancouver, B.C., Canada; <sup>3</sup>University of British Columbia Faculty of Pharmaceutical Sciences, Vancouver, B.C., Canada; <sup>4</sup>University of British Columbia Faculty of Pathology and Laboratory Medicine, Vancouver, B.C., Canada

## **FRONTMIND: A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF TAFASITAMAB + LENALIDOMIDE + R-CHOP VERSUS R-CHOP ALONE FOR NEWLY DIAGNOSED HIGH-INTERMEDIATE AND HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA**

Umberto Vitolo<sup>1</sup>, Grzegorz S. Nowakowski<sup>2</sup>, John M. Burke<sup>3</sup>, Christopher P. Fox<sup>4</sup>, Marek Trnny<sup>5</sup>, Annalisa Chiappella<sup>6</sup>, Maeve Waldron-Lynch<sup>7</sup>, Nira Hadar<sup>7</sup>, Alok Pachori<sup>7</sup>, Georg Lenz<sup>8</sup>, <sup>1</sup>Candiolo Cancer Institute, FPO-IRCCS, Candiolo (Torino), Italy; <sup>2</sup>Division of Hematology, Mayo Clinic, Rochester, MN, USA; <sup>3</sup>Department of Hematology, US Oncology Research and Rocky Mountain Cancer Centers, Aurora, CO, USA; <sup>4</sup>Department of Clinical Hematology, Nottingham University Hospitals NHS, Nottingham, UK; <sup>5</sup>1<sup>st</sup> Department of Medicine, First Medical Faculty, Charles University and General University Hospital, Prague, Czech Republic; <sup>6</sup>Division of Hematology & Stem Cell Transplant, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milano, Italy; <sup>7</sup>MorphoSys US, Boston, MA, USA; <sup>8</sup>Department of Medicine A – Haematology and Oncology, University Hospital Münster, Münster, Germany

## **PREFERENCES AND PERCEPTIONS REGARDING TREATMENT DECISION-MAKING FOR RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL)**

Mirko Vukcevic, PharmD, PhD<sup>1</sup>, Mallory Yung, MPH<sup>2</sup>, Mali Khan<sup>3</sup>, Bethany Houpt, MPH<sup>3</sup>, Frederick Schnell, MD, FACP<sup>4</sup>, <sup>1</sup>MorphoSys AG, Planegg, Bavaria, Germany; <sup>2</sup>Health Management Academy, Washington, DC, USA; <sup>3</sup>Avalere Health, Washington, DC, USA; <sup>4</sup>Community Oncology Alliance, Washington, DC, USA

## **A PHASE II STUDY OF ZANUBRUTINIB-BASED INDUCTION AND MAINTENANCE THERAPY IN YOUNG AND FIT PATIENTS WITH UNTREATED MANTLE CELL LYMPHOMA (BRIDGE): A CASE SERIES REPORT**

Xiaoxiao Wang, Qingqing Cai, Zhiming Li, Yan Gao, Yi Xia, Xuanye Zhang, He Huang, Bin Bai, and Huiqiang Huang, Sun Yat-Sen University Cancer Center, Guangzhou, China

**CPO107, A NOVEL CD20-DEPENDENT CD47-TARGETING BISPECIFIC FUSION PROTEIN FOR ADVANCED CD20-POSITIVE NON-HODGKINS LYMPHOMA**

LP Song, Y Li, WR Ye, T Sheng, HH Zhang, XM Li, JN Jia, H Xu, XH Lin, YF Su, YS She, YJ Cheng, AT Wu, L Yang, ZX Zhang, JX Hu, C Chen, DF Liu, CY Zeng, Y Fan, XD Wang, Q Wang, CSPC-Shanghai JMT-BIO Technology Co., Ltd (Shanghai, China) & Conjupro Biotherapeutics Inc. (NJ, United States)

**PRIMARY MEDIASTINAL B-CELL LYMPHOMA PRESENTING AS CHEST PAIN IN A YOUNG WOMAN AND TREATED WITH EPOCH-R**

Chloe Weidenbaum, DO, MPH; Akanksha Kushwah, MD; Jonathan Abbas, MD; Ariana Geromes, MD, University of Tennessee Health Science Center – Nashville, Internal Medicine Residency; Ascension Saint Thomas, Nashville, TN 37203.

**BELLWAVE-003: PHASE 2 STUDY OF THE BTK INHIBITOR NEMTABRUTINIB IN HEMATOLOGIC MALIGNANCIES**

Ohad Benjamini<sup>1</sup>; Sarit Assouline<sup>2</sup>; David Lavie<sup>3</sup>; Yan Xu<sup>4</sup>; Jing Yang<sup>4</sup>; Mohammed Z. H. Farooqui<sup>4</sup>; Arvind Chaudhry<sup>5</sup>, <sup>1</sup>Sheba Medical Center, Rama Gan, Israel; <sup>2</sup>Jewish General Hospital, Montreal, QC, Canada; <sup>3</sup>Hadassah Medical Center, Jerusalem, Israel; <sup>4</sup>Merck & Co., Inc., Kenilworth, NJ, USA; <sup>5</sup>Summit Cancer Centers, Spokane Valley, WA, USA

**GB5121 IS A NOVEL, IRREVERSIBLE, COVALENT BTK INHIBITOR WITH HIGH SELECTIVITY AND CNS-PENETRANCE FOR TREATMENT OF CNS MALIGNANCIES**

Isharat Yusuf, David Guimond, Zachary Naiman, Theodore Schiff, Bryan Clemons, Bryanna Paulson, Kay Hou, Kristen Taylor Meadows, Mark Rose, Laura Carter, Gossamer Bio, Inc., San Diego, CA, USA

**TIDAL: PRIMARY ANALYSIS OF A GLOBAL PHASE II STUDY OF THE EFFICACY AND SAFETY OF ZANDELISIB ADMINISTERED BY INTERMITTENT DOSING (ID) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)**

Andrew D. Zelenetz<sup>1</sup>, Nishitha Reddy<sup>7</sup>, Tycel Phillips<sup>9</sup>, Joanne Li<sup>12</sup>, Weiming Xu<sup>12</sup>, Michel Azoulay<sup>13</sup>, Richard G. Ghalie<sup>12</sup>, Pier L. Zinzani<sup>14</sup>, <sup>1</sup>Memorial Sloan Kettering Cancer Center, New York, NY, USA; <sup>2</sup>Vanderbilt University, Nashville, TN, USA; <sup>9</sup>University of Michigan Health System, Ann Arbor, MI, USA; <sup>12</sup>MEI Pharma, Inc., San Diego, CA, USA; <sup>13</sup>Kyowa Kirin, Princeton, NJ, USA; <sup>14</sup>University of Bologna, Bologna, Italy

**REAL-WORLD USE OF MOGAMULIZUMAB AMONG PATIENTS WITH MYCOSIS FUNGOIDES AND SÉZARY SYNDROME BEFORE AND DURING COVID-19 IN THE UNITED STATES**

Yang Zhao<sup>1</sup>, Jackson Tang<sup>1</sup>, Huanxue Zhou<sup>2</sup>, Takeshi Takahashi<sup>3</sup>, Takenobu Nomura<sup>3</sup>, Eslie Dennis<sup>1</sup>, Ahmad Halwani<sup>4</sup>, <sup>1</sup>Kyowa Kirin, Inc., Bedminster, NJ, USA; <sup>2</sup>KMK Consulting, Morristown, NJ, USA; <sup>3</sup>Kyowa Kirin Co. Ltd., Tokyo, Japan; <sup>4</sup>University of Utah Huntsman Cancer Institute, Salt Lake City, UT, USA

**INSURE: A GLOBAL POOLED ANALYSIS (INSIGHT MM, UVEA-IXA, AND REMIX) OF PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH IXAZOMIB-LLENALIDOMIDE-DEXAMETHASONE (IRD) IN ROUTINE CLINICAL PRACTICE**

Jeffrey A. Zonder, <sup>1</sup>Xavier Leleu, <sup>2</sup>Mario Boccadoro, <sup>3</sup>Hans C. Lee, <sup>4</sup>Margaret Macro, <sup>5</sup>Karthik Ramasamy, <sup>6</sup>Cyrille Hulin, <sup>7</sup>Jiri Silar, <sup>8</sup>Matyas Kuhn, <sup>9</sup>Kaili Ren, <sup>9</sup>Nawal Bent-Enakhil, <sup>10</sup>Sylvie Bouillie, <sup>11</sup>Dasha Cherepanov, <sup>9</sup>Dawn Marie Stull, <sup>12</sup>Evangelos Terpos<sup>13</sup>, <sup>1</sup>Barbara Ann Karmanos Cancer Institute / Wayne State University School of Medicine, Detroit, MI, USA; <sup>2</sup>Pôle Régional de Cancérologie, Department of Hematology, CHU La Milétrie-Poitiers, Poitiers, France; <sup>3</sup>Division of Hematology, University of Torino, Torino, Italy; <sup>4</sup>M.D. Anderson Cancer Center, Houston, TX, USA; <sup>5</sup>CHU de Caen, Caen, France; <sup>6</sup>Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, Oxfordshire, UK; <sup>7</sup>CHU de Bordeaux, Bordeaux, France; <sup>8</sup>Institute of Biostatistics & Analyses, Ltd, Brno, Czech Republic; <sup>9</sup>Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA; <sup>10</sup>Takeda Pharmaceuticals International AG, Opfikon, Switzerland; <sup>11</sup>Takeda France SAS, Paris, France; <sup>12</sup>Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA, USA, <sup>13</sup>Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

# CONFERENCE SPONSORS

---

## *University of Nebraska Medical Center (Accredited Provider)*

As Nebraska's only public academic health sciences center, the University of Nebraska Medical Center (UNMC) is committed to the education of a 21st century health care work force, to finding cures and treatments for devastating diseases, to providing the best care for patients, and to serving our state and its communities through award-winning outreach. UNMC is also committed to embracing the richness of diversity and is a major economic engine for the state of Nebraska. Led by Chancellor Jeffrey P. Gold, MD, UNMC has six colleges, two institutes, and a graduate studies program, serving nearly 4,000 students in more than two dozen programs. As an academic health science center, UNMC offers patients world-class health care, backed by the latest research innovations and practiced by faculty training the next generation of health care providers. With our hospital partner, Nebraska Medicine, UNMC provides services in about 50 specialties, including cancer, neurosciences, heart disease and others. Through this unique combination of academic, scientific, and health care experience, UNMC transforms the discoveries of the laboratory and theory of the classroom into breakthroughs for health.

The mission of the UNMC Continuing Education Programs is to provide specialized and inter-professional educational activities and support innovative research that facilitate individual skills and team-based performance that improves outcomes for patients and communities. Accordingly, UNMC's continuing education efforts aim to enhance the knowledge, skills, attitudes, competence and performance of health care professionals, ultimately improving patient outcomes and community health. This mission statement drives and unifies the continuing education efforts of all colleges and departments at UNMC.

The UNMC Center for Continuing Education (UNMC CCE) is one of this country's oldest accredited providers of continuing education to physicians, started in 1958. By 1967, UNMC CCE, was one of the first seven medical school programs to be ACCME accredited. Throughout its history, UNMC CCE's level and number of activities have grown in certified activities offered, variety of topics, delivery modes, and diversity of audience participants. UNMC CCE offers a broad range of activities from primary care issues to the latest developments in medicine and draws attendees throughout the region, nationally and internationally.

The UNMC College of Nursing Continuing Nursing Education (UNMC CON CNE) has been serving the profession since 1967. Through the creation of engaging continuing nursing education products using state-of-the-art technologies and innovative educational modalities, we strive to improve patient outcomes in Nebraska and around the globe. Our highly developed technical capabilities include instructional design and module development, video streaming, learning activity hosting, custom web development, visual design, dynamic web pages, and data collection, storage, and analysis. The UNMC CON CNE is approved by the California Board of Registered Nursing, and is able to take accredited programs into all 50 states and beyond.

In pursuit of our collective mission, UNMC CCE and UNMC CON CNE work collaboratively to sponsor multi-professional educational activities designed to improve the performance of the health care team and thus patient outcomes. To forward an integrated team-based approach and to facilitate multi-disciplinary and specialized training, UNMC achieved Joint Accreditation provider status effective through November 2024.

## *UNMC Department of Internal Medicine - Division of Oncology and Hematology*

Renowned for the diagnosis, therapy, and research of lymphoma, the UNMC Department of Internal Medicine, Division of Oncology and Hematology has treated patients from all over the world. Patients come for consultation, initial diagnosis, second opinions, standard chemotherapy, participation in clinical research trials, stem cell transplants, and chimeric antigen receptor (CAR) T-cell therapies.

The Division of Oncology and Hematology is comprised of 32 faculty and physicians, with six specializing in lymphoma. The Division is interested in the diagnosis and treatment of all malignancies (cancers). Treatment may include chemotherapy, radiation therapy, immunotherapy, pathway targeted agents, or cellular therapies, including CAR T-cell therapy and bone marrow transplantation.

The Division's physicians specialize in many types of cancers including lymphomas, leukemia, multiple myeloma, urologic, breast, lung, gastric and pancreatic, neuro-oncologic, brain cancer, melanoma, hepatocellular, and other solid tumors.

## Nebraska Medicine

Nebraska Medicine is the most esteemed academic health system in the region, consisting of 809 licensed beds at its two hospitals, more than 1,000 physicians, and 40 specialty and primary care clinics in Omaha and surrounding areas.

Nebraska Medicine and UNMC, its research and education partner, share the same mission: to lead the world in transforming lives to create a healthy future for all individuals and communities through premier educational programs, innovative research and extraordinary patient care.

Nebraska Medicine traces its roots back to 1869 with the founding of Omaha's first hospital. In the decades since, it has built an international reputation for breakthroughs in cancer care, organ transplantation and treatment of infectious diseases.

In 2017, Nebraska Medicine earned the Bernard A. Birnbaum, MD Quality Leadership Award from Vizient, Inc. which recognizes it in the top ten quality academic health systems in the United States. For five straight years, Nebraska Medicine has also been named to Becker's Hospital Review's list of 100 Great Hospitals in America.

## Fred & Pamela Buffett Cancer Center

The UNMC Fred & Pamela Buffett Cancer Center is the region's only National Cancer Institute (NCI) designated cancer center and is a member of the National Comprehensive Cancer Network (NCCN). The NCCN is an alliance of the nation's 31 leading cancer centers that develop and institute standards of care for the treatment of cancer and perform outcomes research with the goal of ensuring the delivery of high-quality, cost-effective services to cancer patients nationwide.

Five years after its opening, the Fred & Pamela Buffett Cancer Center continues to lead the world in the battle against cancer. By harnessing the most advanced biomedical and technological tools available, we are increasingly identifying the drivers behind cancer and creating precise therapies that improve outcomes. Through the use of genomics and other new diagnostic tools, we are employing precision medicine to customize therapies and care for each cancer patient.

While all forms of cancer will be treated at the Fred & Pamela Buffett Cancer Center, because of their prevalence in society and the center's potential to have a significant impact in their treatment, the following focus areas have been selected: breast cancer and other women's cancers, head and neck cancers, leukemia and lymphoma, lung cancer, pancreatic and gastrointestinal cancers, and prostate cancer.

The Fred & Pamela Buffet Cancer Center, along with the C.L. Werner Cancer Hospital, aim to provide the side-by-side, rapid development of therapeutics and delivery to patients with cancer.



Photo courtesy of HDR © 2017 The Digital Sky

SAVE THE DATE



University of Nebraska  
Medical Center  
Nebraska Medicine

# 2024 PAN PACIFIC **LYMPHOMA** CONFERENCE

July 15-19 • Hyatt Regency Maui

**CALL FOR ABSTRACTS**

Deadline: Friday, March 29, 2024



[www.unmc.edu/panpacificlymphoma](http://www.unmc.edu/panpacificlymphoma)